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Summary 
Human immunodeficiency virus type 1 (HIV-1) infection causes a life-long chronic 
disease despite the tremendous success of combination antiretroviral therapy 
(cART). This is due to the ability of HIV-1 to persist in latent forms in long-lived 
infected cells. Currently approved antiretroviral drugs target multiple steps in the viral 
life cycle. Thus, latent cellular reservoirs of HIV-1 remain untouched and represent 
one of the major obstacles towards the goal of curing HIV-1 infection. 
The mechanisms of induction and maintenance of HIV-1 latency have not been fully 
resolved so far. Besides regulation by transcription factors and/or epigenetic 
modulation of the proviral DNA, one hypothesis suggests that HIV-1 latency may be 
mediated by the intracellular machinery governing innate antiviral defences, such as 
RNA-interference. This mechanism is mediated by small noncoding RNAs, which 
bind to complementary mRNA and finally lead to cleavage of the mRNA or 
suppression of translation. HIV-1 latency could be induced by targeting viral or 
cellular RNA necessary for viral replication. 
 
Chapter 1 describes the establishment of a method to measure viral RNAs with 
single copy sensitivity. Quantitative PCR (qPCR) using fluorescent hydrolysis probes 
(FH-probes) of variable HIV-1 genomes can result in underestimation of viral copy 
numbers due to mismatches in the FH-probe’s target sequences. Particularly for 
detection of viral RNA in patients, successfully treated with cART, or in latently 
infected cells, highly sensitive qPCRs are essential. The study resulted in empirically 
validated novel principles of FH-probe design regarding conservation and qPCR 
performance. Several FH-probes used to quantify HIV-1 DNA over 6 orders of 
magnitude approached single copy sensitivity. Moreover, application of an algorithm 
to scan sequence databases for FH-probes with optimal phylogenetic conservation, 
allowed to identify functional FH-probes in various regions of the HIV-1 genome 
approaching coverage of the global HIV-1 pandemic. 
 
The second chapter illustrates the development of a method to efficiently select and 
sequence small noncoding RNAs (sncRNAs), the key molecules of RNA interference. 
Since HIV-1 encoded sncRNAs represent only a small minority of sncRNAs in an 
infected cell, their detection remains difficult and reported frequencies of HIV-1 
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sncRNAs are usually <0.5%, if at all. Our approach was to enrich sequences 
homologous to HIV-1 by hybridization capture using HIV-1 ssDNA hybridization 
probes attached to Streptavidin beads. With this optimized selection method we were 
able to enrich low abundant HIV-1 sncRNAs more than 100-fold, i.e., >70% of 
captured sncRNAs were derived from HIV-1. This method was further applied to 
characterize the scope of viral sncRNA expression in primary HIV-1 infected cells. A 
multitude of HIV-1 sncRNAs was identified, distributed throughout the HIV-1 genome, 
yet, they clustered in contigs with hot-spots at distinct sites. Furthermore, hybrids of 
sense and antisense sncRNAs of one contig inhibit HIV-1 replication in primary 
macrophages demonstrating one possible function of these sncRNAs. 
 
The third section refers to a study published in collaboration with colleagues from our 
research group. The study focused on monitoring HIV-1 RNA transcription patterns in 
peripheral blood mononuclear cells (PBMC) during cART in acutely HIV-1 infected 
patients to assess the effect of early treatment on cellular viral reservoirs (Schmid et 
al., 2010). I developed the appropriate qPCR protocols (please compare first 
chapter), assisted with the search for optimal patient matched primers and FH-
probes for highly sensitive qPCRs, supervised the qPCR procedures, and helped in 
analyzing and interpreting the qPCR data. This study showed that early cART in 
acute HIV-1 infection significantly depleted the number of transcriptionally active 
proviruses when compared to levels detected in patients starting ART during chronic 
HIV-1 infection. Therefore, future studies aiming at HIV-1 eradication should be 
initiated in patients during acute infection. 
 
In conclusion, my thesis mainly focused on the establishment of highly sensitive and 
improved methods for the detection of HIV-1 genomes and HIV-1 derived small 
noncoding RNAs, respectively, to enable detailed studies of various aspects of HIV-1 
latency. Thus, quantitative PCR protocols were developed to detect a broad range of 
highly diverse HIV-1 variants with single copy sensitivity, and a novel approach for 
very efficient enrichment of low abundant HIV-1 sncRNAs was established. Both 
methods lay the foundation for further studies, not only in the field of HIV-1, but also 
in other research areas where highly sensitive methods for the detection of RNA and 
sncRNAs are needed. 
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Zusammenfassung 
Eine Infektion durch das Humane Immunodefizienz-Virus vom Typ 1 (HIV-1) 
verursacht eine lebenslange chronische Erkrankung, trotz einer sehr erfolgreichen 
kombinierten antiretrovirale Therapie (engl. cART). Ein wesentlicher Grund ist die 
Fähigkeit von HIV-1 in eine Latenzphase einzutreten und sich somit für das 
Immunsystem unsichtbar zu machen. Die mit HIV-1 latent infizierten Zellen können 
Jahre, wenn nicht Jahrzehnte überleben, ehe sie in die produktive Phase übergehen. 
Die heute zugelassenen antiretroviralen Medikamente greifen an verschiedensten 
Stellen in den viralen Lebenzyklus ein. Das latente zelluläre Reservoir von HIV-1 
bleibt jedoch bis zum heutigen Tage unangetastet und repräsentiert eines der 
grössten Hindernisse auf dem Weg zur Heilung einer HIV-1 Infektion. 
Die Mechanismen der Induktion und Erhaltung der HIV-1 Latenz wurden bis heute 
noch nicht vollständig gelöst. Neben einer Regulierung durch Transkriptionsfaktoren 
und/oder epigenetische Modulationen der proviralen DNA, besagt eine dritte 
Hypothese, dass die HIV-1 Latenz durch intrazelluläre Mechanismen, welche für die 
angeborene antivirale Abwehr zuständig sind, verursacht werden könnte. Ein 
Beispiel für eine solche angeborene antivirale Abwehr ist die RNA Interferenz. Dieser 
Prozess wird durch kleine nicht-kodierende RNAs gesteuert, welche sich an 
komplementäre mRNAs binden und schlussendlich zu einer Zerteilung dieser 
mRNAs oder einer Unterdrückung der Translation führen. HIV-1 Latenz könnte daher 
durch eine gezielte Degradation von viraler oder zellulärer RNA, welche notwendig 
für die virale Replikation sind, verursacht werden. 
 
Kapitel 1 beschreibt die Einführung einer Methode um virale RNAs mit der 
Sensitivität einer einzelnen Kopie messen zu können. Die quantitative PCR (qPCR) 
variabler HIV-1 Genome mit FH-Proben (engl. fluorescent hydrolysis probes) kann, 
im Falle einer Diskrepanz mit der Ziel-Sequenz der FH-Probe, zu einer 
Unterschätzung der viralen Kopienzahl führen. Besonders beim Nachweis viraler 
RNA in erfolgreich mit ART behandelter Patienten, oder in latent infizierten Zellen, 
sind höchst sensitive qPCRs entscheidend. Aus der Studie ergaben sich empirisch 
bestätigte neue Prinzipien - bezüglich Konservierung und qPCR Effizienz - zur 
Gestaltung von FH-Proben. Bei mehreren FH-Proben, welche zur Quantifizierung 
von HIV-1 DNA über 6 Grössenordungen angewendet wurden, lag die Sensitivität bei 
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einer Kopie. Zusätzlich ermöglichte der Gebrauch eines Algorithmus die 
Durchsuchung von Sequenz Datenbanken nach FH-Proben mit optimaler 
phylogenetischer Konservierung. Dies ermöglichte die Identifizierung von 
funktionellen FH-Proben an verschiedenen Stellen des HIV-1 Genoms, welche 
annähernd die globale HIV-1 Pandemie abdecken. 
 
Das zweite Kapitel illustriert die Entwicklung einer effizienten Methode um kleine 
nicht-kodierende RNAs (engl. sncRNAs) zu selektionieren und sequenzieren, welche 
die Schlüsselmolekule der RNA Interferenz darstellen. Da HIV-1 kodierte sncRNAs 
nur eine kleine Minderheit der sncRNAs einer infizierten Zelle darstellen, bleibt der 
Nachweis schwierig, und die Häufigkeit dieser HIV-1 sncRNAs wird normalerweise 
als <0.5%, wenn überhaupt vorkommend, beschrieben. Unser Ansatz war HIV-1 
homologe sncRNAs durch Hybridisierung mit HIV-1 DNA Hybridisierungs-Proben 
anzureichern. Mit dieser optimierten Methode war es uns möglich die selten 
vorkommenden HIV-1 sncRNAs mehr als 100-fach anzureichern, das heisst >70% 
der selektionierten sncRNAs stammten von HIV-1. Diese Methode wurde auch 
angewendet um die Bandbreite der viralen sncRNA Expression in primären HIV-1 
infizierten Zellen zu charakterisieren. Eine Vielzahl von HIV-1 sncRNAs wurde 
identifiziert, welche auf dem ganzen HIV-1 Genom verteilt sind, und doch in 
gewissen Contigs in spezifischen Regionen gehäuft anzutreffen sind. Zusätzlich 
konnten wir zeigen, dass Hybride von sncRNAs mit positiver und negativer Polarität 
die HIV-1 Replikation in primären Makrophagen inhibieren, was eine mögliche 
Funktion dieser sncRNAs darstellen könnte. 
 
Der dritte Teil bezieht sich auf eine Studie, die ich in Zusammenarbeit mit Kollegen 
von unserer Forschungsgruppe durchgeführt habe. Die Studie hatte die 
Aufzeichnung der HIV-1 RNA Transkriptions Muster in peripheren mononukleären 
Blutzellen (engl. PBMC) zum Fokus. Diese wurden während der medikamentösen 
Behandlung von akut HIV-1 infizierten Patienten gemessen, um den Effekt der frühen 
Behandlung auf das virale Reservoir abzuschätzen (Schmid et al., 2010). Meine 
Beträge waren das Erstellen der qPCR Protokolle (im ersten Kapitel beschrieben), 
die Assistenz bei der Suche nach optimal an die viralen Sequenzen der Patienten 
angepassten Primern und FH-Proben, sowie die Mithilfe bei der Analyse und 
Interpretation der Resultate der qPCRs. Die Studie konnte zeigen, dass frühe ART 
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während der akuten HIV-1 Infektion die Anzahl der transkriptionell aktiven Proviren 
signifikant senkt, verglichen mit Patienten, die die Behandlung erst während der 
chronischen Phase begannen. Daher sollten zukünftige Studie, welche die 
Eradikation von HIV-1 zum Ziel haben, bei Patienten während der akuten Phase 
initiiert werden. 
 
Zusammenfassend war meine Arbeit fokussiert auf die Etablierung von sehr 
sensitiven und optimierten Methoden zum Nachweis von HIV-1 Genomen und 
kleinen nicht-kodierenden von HIV-1 stammenden RNAs, um detaillierte Studien zu 
verschiedenen Aspekten der HIV-1 Latenz durchführen zu können. Daher wurden 
quantitative PCR Protokolle entwickelt, um ein möglichst breites Spektrum stark 
unterschiedlicher HIV-1 Varianten mit grosser Sensitivität nachzuweisen. Auch wurde 
ein neuer Ansatz für eine sehr effiziente Anreicherung von selten vorkommenden 
HIV-1 sncRNAs gefunden. Beide Methoden legen die Grundlage für zukünftige 
Studien nicht nur im Feld von HIV-1, sondern auch in anderen Forschungsgebieten, 
in welchen hoch sensitive Methoden zum Nachweis von RNA und sncRNAs 
gebraucht werden. 
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Introduction 
1. Human immunodeficiency virus type 1 
1.1 History and Epidemiology 
In the early 1980s, a mysterious disease pattern began to spread among men who 
have sex with men in New York1, San Francisco and Los Angeles2 causing low CD4 
T-cell count, various bacterial infections and Kaposi’s sarcoma (KS), an otherwise 
very rare skin cancer. A few years later, in 1983, Françoise Barré-Sinoussi and Luc 
Montagnier3 reported to have found particles of a virus connected to this disease 
pattern named AIDS (acquired immunodeficiency syndrome). The virus is known 
today as human immunodeficiency virus type 1 (HIV-1).  
Since the mid 1990s, effective treatment is available against HIV-1 by combining 
several antiretroviral drugs. Combination antiretroviral therapy (cART) is able to clear 
almost all extracellular viruses and significantly reduces morbidity and mortality of 
patients4. However, cART is not able to cure HIV-1 infection, as the virus hides in 
latently infected cells and immediately reactivates upon cessation of treatment.  
Almost 30 years after the first mentioning of AIDS, in 2009, around 33 million people 
worldwide were infected with HIV-1; 2.6 million people became newly infected and 
1.8 million people died of AIDS (UNAIDS, 2010). The HIV pandemic is caused by 
HIV-1. In 1986, HIV type 2 (HIV-2) was isolated from a West African patient with 
AIDS5. HIV-2 has a lower virulence and infectivity than HIV-1, and it is mainly 
prevalent in Western Africa6. 
 
1.2 Genome and Morphology 
HIV-1 is a lentivirus and belongs to the family of retroviruses. Its genome is 
composed of two identical single-stranded RNA molecules (~9.2-9.4 kb) and nine 
genes. The proviral genome is flanked by the 5’ and 3’ LTRs (long terminal repeats) 
(Fig. 1a). The 5’ LTR serves as a promoter for the RNA-polymerase II. HIV-1 
encodes three structural and enzymatic genes, four accessory and two regulatory 
genes7.  
The HIV-1 RNA genome contains, like human cellular messenger RNA (mRNA), a 7-
methylguanosine cap at the 5’ end and is polyadenylated at the 3’ end. The two LTRs 
are only present in parts in the HIV-1 RNA, namely the R (repeat) region is the only 
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repetitive sequence that exists at the 5’ and the 3’ end of the HIV-1 RNA (Fig. 1b). 
The R region forms a very strong and characteristic secondary structure, which is 
termed TAR (trans-activating response region) and serves as a binding site for the 
Tat (transactivator of transcription) protein8,9. The TAR element is one of the most 
structured regions, however, the whole HIV-1 RNA genome displays a extensive 
secondary structure10. Adjacent to the U5 region is the primer binding site (PBS), 
which is complementary to and binds the 3’ end of host cellular tRNALys11,12. The 
tRNALys functions as a primer for the reverse transcriptase to initiate the synthesis of 
the minus strand of the viral DNA. Around 700 nucleotides (nt) downstream of the 
start of transcription the dimerization initiation site (DIS) is located, which induces the 
dimerization of the 2 RNA copies that are incorporated into one virion. At the 3’ end 
of the HIV-1 RNA, a polyadenylation signal is located in the R region and leads to 
synthesis of a poly(A)-tail, whereas this signal is suppressed at the 5’ end13. 
 
The three structural and enzymatic genes are gag (group-specific antigen), pol 
(polymerase), and env (envelope) (Fig. 1b). Gag encodes four capsid proteins after 
cleavage: matrix (MA, p17), capsid (CA, p24), nucleocapsid (NC, p9), and p6 (Fig. 
1c). The polyprotein Pol is processed into three enzymatic proteins – protease (PR), 
reverse transcriptase (RT), and integrase (IN). The RT transcribes viral single-
stranded RNA (ssRNA) into DNA, which is integrated by integrase into the host 
genome and viral precursor poly-proteins are finally cleaved by protease into 
functional proteins14. Env (envelope) encodes gp160 which is cleaved to surface 
glycoprotein SU (gp120) and transmembrane glycoprotein TM (gp41) by the cellular 
protease furin15. The regulatory genes are tat (transactivator of transcription) and rev 
(regulator of virion expression). Tat acts as transcriptional activator through binding 
to the flanking region, the TAR region in the LTR8,9. Rev transports viral RNA from 
the nucleus to the cytoplasm16-18. The accessory genes of HIV-1 are nef (negative 
effector), vif (virion infectivity factor), vpu (viral protein u), and vpr (viral protein r). The 
Nef protein is important for the efficiency of virus replication19. Among other 
functions, Vif inhibits the function of APOBEC3G (apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide-like 3G), which is a deaminase with antiviral function20. 
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Figure 1: HIV-1 provirus, RNA genome, proteins and virion structure. a) The HIV-1 
provirus is integrated into the human genome. Integrated HIV-1 DNA is flanked at the 5’ and 
at the 3’ end by 2 complete long terminal repeats (LTRs: U3-R-U5). b) Transcription of the 
HIV-1 RNA genome starts in the R region of the 5’ LTR and ends with the R of the 3’ LTR. 
HIV-1 encodes three structural and enzymatic (gag, pol, env), four accessory (vif, vpu, vpr, 
nef), and two regulatory genes (tat, rev). c) 3 genes of the HIV-1 genome encode structural 
proteins and enzymes: the Gag precursor poly-protein is processed into MA (matrix), CA 
(capsid), NC (nucleocapsid) and p6, pol encodes the enzymes PR (protease), RT (reverse 
transcriptase) and IN (integrase), while env is encoding the two surface glycoproteins, gp120 
and gp41. d) The HIV-1 virion is surrounded by a lipid membrane derived from the host cell 
(black) in which HIV-1 Env proteins (red) are embedded. The 2 HIV-1 RNA copies are 
surrounded by nucleocapsid proteins. In addition, proteins necessary for reverse 
transcription and integration of the provirus are incorporated into the virion. 
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The structural proteins form the virion, which is about 100-130 nm in diameter (Fig. 
1d). Its outer layer consists of a lipid membrane – derived from the host cell – in 
which the viral envelope proteins, gp120 and gp41, are embedded. These envelope 
proteins are essential for attachment and entry of the virion into the target cell via its 
receptor, CD4. The inner surface of the membrane is lined by the matrix. The capsid 
forms a conical core encircling the RNA, which is coated by nucleocapsid. In addition 
to viral proteins, the membrane and the interior of the virus contain proteins derived 
from the host cell7,21. 
 
1.3 Life cycle of HIV-1 
When a HIV-1 virion infects a cell, homotrimeric Env proteins first bind to the cellular 
CD4 receptor and subsequently to a chemokine co-receptor, predominantly either 
CCR5 or CXCR422 (Fig. 2). This interaction results in conformational changes leading 
to fusion of the viral and the host cell membranes. The viral core enters the cell. The 
single-stranded RNA is converted to double-stranded DNA by the HIV-1 encoded 
reverse transcriptase. The DNA enters the nucleus and is integrated into the host 
genome by the viral integrase, forming the provirus23. 
In this stage, the provirus can hide in the infected cell for years without being 
transcribed or only being transcribed at low levels, which is then called the latent 
stage. During productive infection, the proviral DNA is transcribed by the cellular 
RNA polymerase II. The first transcripts that appear are mRNAs which encode the 
regulatory proteins Tat, Rev and Nef. Those mRNAs are multiply spliced by the 
cellular splicing machinery and, thus, are able to be exported into the cytoplasm24. 
The Rev and the Tat proteins subsequently return to the nucleus. Rev is responsible 
for efficient export of unspliced and singly spliced viral mRNAs to the cytoplasm25. 
Tat mediates transcriptional activation by binding to the TAR stem-bulge-loop26. 
Subsequently, in the late phase, unspliced and singly spliced mRNAs are produced 
and exported to the cytoplasm. Singly spliced mRNAs encode for the Env proteins 
and the accessory proteins Vif, Vpu and Vpr. From the unspliced RNA Gag and Pol 
proteins are translated14. Finally, 2 unspliced RNA molecules and several proteins 
assemble, and new virions are budding from the cell27. 
INTRODUCTION 
 13
 
 
Figure 2: HIV-1 lifecycle. Viral fusion and entry requires the binding of glycoprotein gp120 
to CD4 receptors at the cell surface as well as to chemokine co-receptors, either CCR5 or 
CXCR4. The viral core enters the cytoplasm and viral RNA is converted into proviral double-
stranded DNA (dsDNA) by the reverse transcriptase. The pre-integration complex is 
transported into the nucleus through the nuclear pore complex (NPC), and the dsDNA either 
circularizes as one or two long terminal repeat-containing circles or is integrated into a host 
genome. After integration, the provirus can remain quiescent, existing in a permanent post-
integration latent state. Upon activation, the viral genome is transcribed by the cellular RNA 
polymerase II. This process is influenced by cellular transcription factors (NF-κB, NFAT and 
SP1) and the viral transactivator Tat. The viral protein Rev regulates the export of unspliced 
or singly spliced viral mRNAs to the cytoplasm, which are translated into regulatory and 
structural viral proteins. New virions assemble and bud through the cell membrane, maturing 
through the activity of the viral protease. (adapted from Coiras et al., 2009 28) 
 
 
1.4 Transmission and course of infection 
HIV-1 is transmitted through body fluids and an infection takes place through contact 
with contaminated blood or oral, anal, and vaginal sexual intercourse. HIV-1 positive 
women can infect their babies during pregnancy, birth, or through breast feeding29,30. 
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The first phase of infection, the acute phase, normally lasts 4 to 8 weeks and is 
characterized by very high blood virus levels (viremia) and a dramatic decrease in 
numbers of CD4+ T-cells31. The virus preferentially infects CD4+ T-lymphocytes, as 
well as dendritic cells and macrophages. The adaptive immune system responds with 
formation of helper CD4+ T-cells, CD8+ cytotoxic T-cells and antibodies, which may 
partially clear the virus from the circulation, but do not wipe out the virus32. 
Nevertheless, this mounting of an HIV-1 specific immune response in the acute 
phase reduces the number of viral particles in the blood stream. 
In the following asymptomatic phase, which lasts between 2 and 15 years, the virus 
constantly replicates and the CD4+ T-cells decrease over time. The symptomatic 
phase, or AIDS stage, occurs, when the CD4+ T-cell levels are low and the HIV-1 
amount in the peripheral blood rises. At this stage, the immune system is 
immunodeficient and highly affective for opportunistic infections30. 
  
1.5 HIV-1 latency 
Upon initiation of combined antiretroviral therapy (cART), virus replication is 
suppressed and the number of productively HIV-1 infected cells rapidly decrease33,34. 
But latently HIV-1 infected cells can survive for years if not decades during effective 
cART35-37. 
Latency is a powerful survival strategy that many viral and microbial pathogens have 
evolved to persist in the face of host defense38. By temporarily reducing gene 
expression at the cost of forsaking production of progeny, the pathogen can avoid 
destruction by the adaptive immunity, which recognizes mainly infected cells actively 
producing foreign antigens. In order to use latency as a valuable survival strategy, 
the pathogen will eventually have to reverse the condition of latency to a state of 
offspring production. Thus HIV-1 latency is reversible and in equilibrium with 
replication36,37,39,40. 
 
1.6 Suggested mechanisms inducing HIV-1 latency 
A first model that attempts to explain the phenomenon of HIV-1 latency is that 
epigenetic modifications, such as chromatin remodelling, lead to a suppression of 
transcription (Fig. 3a and c). Tat is capable of remodelling chromatin in the LTR 
region to enhance the transcription rate41-43. One example of a host silencing 
mechanism efficiently downregulating HIV-1 expression is the recruitment of HDAC1 
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(histone deacetylase 1) to the HIV-1 LTR42,44. HDACs function to remove the acetyl 
group from the N-terminal histone tail, which leads to a condensation of the DNA 
structure and with that a repression of transcription. Consistent with a major role for 
HDACs in establishing HIV-1 latency, many drugs that inhibit HDAC activity, such as 
trichostatin A (TSA) and valproic acid (VPA)45, are effective inducers of HIV-1 
transcription in latently infected cells. Tat also counteracts this mechanism by 
recruiting HATs (histone acetyltransferases) to the LTR which acetylate the histone 
tails, and with that circumvent the transcriptional repression46,47.  
A second hypothesis is that HIV-1 latency is regulated by transcription factors (Fig. 
3b and d). NF-κB is a cellular transcription factor, which is important for HIV-1 
replication. The LTR harbours two binding sites for NF-κB. Upon activation, NF-κB is 
released by its inhibitor IκB and enters the nucleus, where it binds the LTR of HIV-
148. The NF-AT and PKC pathways also affect viral promoter activation in the HIV-1 
LTR49-51. The sequestration of those cellular transcription factors in the cytoplasm of 
resting CD4+ T-cells leads to a transcriptional silencing of HIV-152-54. The most 
notable viral regulator of HIV-1 transcription is Tat, the trans-activator protein. Tat 
mediates transcriptional activation by binding to the TAR stem-bulge-loop26. There it 
mediates recruiting of essential transcription factors, such as the positive 
transcription-elongation factor b (P-TEFb)55,56. When Tat is absent or only present at 
low levels, short prematurely terminated non-polyadenylated transcripts are formed, 
which are not transferred to the cytoplasm40. In the presence of Tat full-length 
transcripts increase up to 100 fold8,57,58. However, in resting CD4+ T-cells expression 
of Tat protein is inefficient and therefore Tat transactivation is presumably absent. 
And a third model suggests that post-transcriptional gene silencing via RNA-
interference is involved (Fig. 3e). Here, a protein complex is guided by a small RNA 
to the complementary mRNA. This interaction finally leads to degradation of the 
mRNA or translational repression.  
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Figure 3. HIV-1 latency is the result of multiple restrictions on HIV-1 expression. a) 
Proviral latency is maintained, in part, by the action of several transcription factors that 
recruit, for instance, histone deacetylases (HDACs) to the HIV-1 LTR promoter, which results 
in condensation of chromatin and subsequently limits the ability of RNA polymerase to initiate 
transcription. b) Key cellular factors that are required for HIV-1 transcription, such as NF-κB 
or P-TEFb, are sequestered in resting CD4+ T cells by cellular regulatory complexes. 
Release and mobilization of these factors is required for proviral expression. c) When histone 
acetyltransferases (HATs) overcome the effect of HDACs, coactivators such as NF-κB can 
recruit RNA polymerase complexes. Production of Tat allows the recruitment of P-TEFb, 
mediating an explosive increase in transcription and the escape of provirus from latency. d) 
The initial wave of Tat production may be restricted by inefficient export of multiply spliced 
HIV-1 mRNAs. Upon cellular activation those mRNAs are relieved by enhanced expression 
of polypyrimidine tract–binding protein (PTB). e) Cellular or possibly viral miRNAs that bind 
HIV-1 mRNAs may also restrict translation of early expressed HIV-1 mRNAs and so reduce 
Tat production. (adapted from Richman et al., 2009 59) 
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2. RNA-interference 
The discovery of RNA interference was preceded by observations of transcriptional 
inhibition by antisense RNA expressed in transgenic plants60. More than 10 years 
later, Fire, Mello, and co-workers described a mechanism that is induced by small 
double-stranded RNAs and finally leads to suppression of protein expression61. 
Today, this process is called RNA interference (RNAi) and known to be mediated by 
regulatory small noncoding RNA (sncRNA). 
 
2.1 Regulatory small noncoding RNAs 
So far, there are three main classes of regulatory sncRNAs known to induce RNA 
interference: the microRNAs (miRNAs), the small interfering RNAs (siRNAs), and the 
PIWI-interacting RNAs (piRNAs). These sncRNAs share the characteristics of having 
a short size (~20-30 nt) and being associated with Argonaute (Ago)-family proteins62. 
The first miRNA, lin-4, was identified in Caenorhabditis elegans63. It plays a key role 
in regulating postembryonic developmental events63. Afterwards, miRNAs were also 
found in plants and other animals, including mammals. They were shown to influence 
a variety of biological processes by RNA-interference, for instance, embryogenesis, 
apoptosis, cell proliferation, and carcinogenesis64. Today, over 1,000 miRNAs 
(www.mirbase.org) are reported alone in human cells, which play a crucial role in the 
regulation of genetic and epigenetic processes. The second group are formed by 
siRNAs that are derived from long double stranded RNA and bind to the target 
mRNA with perfect sequence similarity. They can be either of endogenous, i.e., 
base-paired sense and antisense transcripts, or of exogenous, mainly viral, origin62. 
The third group of regulatory sncRNAs are the piRNAs65. They are derived from long 
single-stranded RNAs and are mainly expressed in germ cells, however, their 
existence could recently be shown also in somatic cells66. 
 
2.2 Biogenesis and function of regulatory small noncoding RNAs 
MicroRNAs are encoded in the genome and their precursors are transcribed by the 
RNA polymerase II, resulting in long either completely or partially double-stranded 
primary transcripts67. Those are trimmed by microprocessors, protein complexes 
consisting of Drosha, an endonuclease with dsRNA specific activity, and the RNA 
binding protein DGCR868,69. The precursor miRNAs (pre-miRNAs) are actively 
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exported to the cytosol by Exportin-570. There they are processed by Dicer, another 
double strand specific endonuclease, into duplexes of 18-25 basepairs (bp)71. Those 
duplexes then bind the RNA induced silencing complex (RISC) whereby one strand 
is integrated into the protein complex and the other is been degraded72. This complex 
of the mature miRNA bound to RISC is then responsible for RNA-interference, by 
either cleaving the complementary target mRNA or repressing the translation.  
SiRNAs are produced in a similar way. They are cleaved by the same endonuclease 
Dicer, and also induce RNA-interference by being incorporated into RISC. However, 
in contrast to the miRNAs, they are derived from complementary double stranded 
RNA progenitors, and ultimately rather lead to degradation of mRNA than to 
translational repression73. 
MiRNAs and siRNAs are not only able to lead to posttranscriptional degradation of 
mRNA or repression of translation but may also induce transcriptional gene silencing 
by epigenetic modifications74. Transcriptional gene silencing acts at the level of DNA 
interactions with promoters and can result in long-term silencing. The most common 
epigenetic modifications induced by sncRNAs are DNA methylation and histone 
modifications74.  
The third group of sncRNAs, piRNAs, are 24-31 nt long and silence transposons in 
animal germ cells. In contrast to siRNAs and miRNAs, they neither require Drosha 
nor Dicer for their biogenesis. Thus, piRNAs are single-stranded RNAs without going 
through a double-stranded intermediate state75,76. 
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Figure 4: Formation and function of small noncoding RNAs. a) SiRNAs are processed 
from complementary double-stranded RNAs (dsRNAs). The enzyme Dicer cleaves dsRNA 
into shorter double-stranded siRNAs of about 20 bp. One strand then assembles into the 
RNA-induced silencing complex (RISC). This complex uses the siRNA guide to identify 
mRNAs with a perfect sequence complementary to the siRNA, leading to cleavage of the 
mRNA. b) MiRNAs are processed from genome-encoded precursors, which fold into 
intramolecular hairpins containing imperfectly base-paired segments. The processing 
generally occurs in two steps, and is catalyzed by the enzymes Drosha (in the nucleus) and 
Dicer (in the cytoplasm). One strand of the resulting miRNA duplex, resembling a siRNA, 
then incorporates into the RISC-complex. Depending on the level of sequence similarity, 
miRNAs induce mRNA degradation or repress their translation. c) PiRNAs are generated 
from long, single-stranded precursors in a process independent of Drosha and Dicer. These 
small RNAs associate with a subfamily of Argonaute proteins called Piwi proteins. This 
complex is thought to silence transposons in animal germ cells. (adapted from Großhans and 
Filipowicz, 2008 77). 
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2.3 Viral microRNAs 
In 2004, the first viral miRNAs were described, which were discovered in Epstein-
Barr virus (EBV) infected human B-cells78. To date, more than 140 viral miRNAs 
(vmiRNAs) have been discovered in herpesviruses79,80 alone, but vmiRNAs were 
also identified in polyomaviruses (SV-40)81 and retroviruses (HIV-1)82-85. 
Of interest, Kaposi’s sarcoma-associated herpesvirus (KSHV) encodes as much as 
12 pre-miRNAs that result in 17 distinct mature vmiRNAs. Those vmiRNAs may play 
critical roles in establishment and/or maintenance of KSHV latent infection86. EBV 
expresses vmiRNAs that target the viral protein LMP1 (latent membrane protein 1), 
which is a transmembrane protein essential for EBV-mediated growth 
transformation87. They were also described to be characteristic for type III latency in 
infected B lymphocytes88. In general, viral miRNAs in herpesviruses appear to be 
involved in latency/lytic switch, immune evasion, cell survival and proliferation89. 
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3. Relationship between HIV-1 and RNA-interference 
3.1 Cellular microRNAs interact with HIV-1 
In 2005, Yeung and colleagues detected changes in cellular miRNA expression 
profiles, i.e., downregulation of a large pool of miRNAs in human HeLa cells 
transfected with HIV-1 plasmid pNL4-390. A second study explored in more detail the 
importance of the miRNA pathway in the control of HIV-1 replication91. Using siRNAs 
against Drosha and Dicer in peripheral blood mononuclear cells (PBMC) from HIV-1 
infected patients, they noticed faster virus replication kinetics in Drosha- or Dicer-
depleted cells, as compared to cells treated with control siRNAs. This result was 
confirmed in latently infected U1 cells; downregulation of Drosha and Dicer led to an 
enhancement of virus replication. Therefore, both Drosha and Dicer contribute to the 
suppression of HIV-1 replication, and potentially are important factors for induction 
and maintenance of HIV-1 latency. 
In the same study, Triboulet and colleagues also demonstrated that HIV-1 infection 
was associated with either up- or down-regulation of cellular miRNA clusters91. As an 
example, the miR-17/92 cluster encoding 7 miRNAs was significantly decreased in 
HIV-1 infected cells. Some miRNAs of this cluster, miR-17-5p and miR-20, may 
target the histone acetyltransferase (HAT) and the HIV-1 Tat cofactor PCAF 
(p300/CBP-asscociated factor), thus, regulate gene expression91. Several other 
studies explored also possible roles of cellular miRNAs to influence HIV-1 replication 
and demonstrated that various cellular miRNAs interfere with HIV-1 gene expression 
and inhibit viral replication92-94. Especially of interest is the study of Huang and co-
workers94 showing that the 3’ end of the HIV-1 mRNAs is targeted and repressed by 
a cluster of cellular miRNAs including miR-28, miR-125b, miR-150, miR-223, and 
miR-382, and that those are enriched in resting CD4+ T-cells as compared to 
activated CD4+ T-cells. Specific inhibitors of these miRNAs substantially 
counteracted their effects on the target mRNAs. Those results indicate that cellular 
miRNAs may play a crucial role in HIV-1 latency. 
In addition, cellular miRNA expression levels were shown to correlate with 
susceptibility of monocytes and macrophages to HIV-1 infection95. Freshly isolated 
monocytes from peripheral blood express significantly higher levels of miRNAs (miR-
28, miR-150, miR-223, and miR-382) that possibly counteract HIV-1 than monocyte-
derived macrophages. Suppression of these anti-HIV-1 miRNAs in monocytes was 
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shown to facilitate HIV-1 infectivity, whereas increase of the anti-HIV-1 miRNA 
expression in macrophages reduced HIV-1 replication. 
 
3.2 HIV-1 counteracts cellular RNA-interference 
The fact that HIV-1 transcription is active and produces new particles in the presence 
of RNAi components suggests that HIV-1 is able to counteract this inhibiting 
mechanism. Various viruses are known to express suppressor of RNA-silencing 
proteins, including NS1 (non-structural protein 1) of influenza96 and Tas 
(transcriptional transactivator) of primate foamy virus97. The HIV-1 transactivator Tat 
was shown to antagonize the intracellular defence system by binding and inhibiting 
its key factor Dicer, which results in shutdown of the RNAi pathway82. Thus, Tat 
expression may prevent intracellular innate responses against virus infection, which 
could otherwise inhibit expression of viral mRNAs or proteins. These findings could 
not be confirmed when Tat was used in physiologically relevant levels98,99.  
Another report demonstrated that TRBP (TAR RNA binding protein), an important 
cofactor of Dicer in the RISC complex, interacts with Tat and its target sequence 
TAR, thus, being an essential component of the viral transactivation complex91. 
Hence, HIV-1 may hijack cellular proteins, as for instance TRBP, which are 
subsequently not available anymore for the RNA-interference pathway.  
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Figure 5. The microRNA pathway can modulate both cellular and viral gene 
expression. Potential mechanisms of the miRNA pathway to induce and maintain HIV‑1 
latency . 1) Cellular miRNAs can target and degrade viral mRNA or repress their translation. 
2) The HIV-1 genome may produce miRNAs, called vmiRNAs, which can target viral RNAs 
and cellular mRNAs. 3) Cellular miRNAs can target cellular factors that are involved in HIV‑1 
replication. 4) Finally, viral products can interfere directly with RNA-interference machinery 
by hijacking Dicer (mediated by Tat) and TRBP (mediated by TAR). (adapted from Coiras et 
al., 2009 28) 
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3.3 HIV-1 encodes viral microRNAs 
Using a computational method designed to find characteristic secondary structures in 
the nucleotide sequences, five candidate pre-miRNAs encoded by different regions 
of the HIV-1 genome were predicted100. So far, one of them has been experimentally 
confirmed in HIV-1 infected cells85,101. Furthermore, two HIV-1 encoded miRNAs and 
one siRNA have been discovered in HIV-1 infected cells82,84,102. Those HIV-1 
sncRNAs are depicted in figure 6. 
 
 
Figure 6. HIV-1 derived miRNAs and siRNAs. Positions, predicted secondary structures 
and proposed cleavage sites of Dicer (red arrows) of the TAR miRNAs85,101, the viral siRNA 
(vsiRNA)82, the miRNA derived from nef (miR-N367)84, and the HIV-miR-H1102 located in the 
U3, are displayed. 
 
 
The first viral miRNA identified was detected in persistently HIV-1 infected MT-4 T 
cells and was derived from the nef region84 (Fig. 6). This miRNA, called miR-N367, 
was detected by Northern blot analysis with probes directed to the nef region. The 
RNA fraction containing small RNA molecules (~25 nt) was subsequently cloned and 
sequenced, confirming the existence of miR-N367. Overexpression of miR-N367 did 
lead to suppression of HIV-1 LTR-driven transcription in reporter gene assays83 
suggesting that this miRNA has the ability to downregulate HIV-1 transcription. 
Additionally, this miRNA was able to downregulate nef expression in the subcapsular 
regions of the spleen in mice, as determined by immunofluorescence and RT-PCR84.  
One year later, Bennasser and co-workers identified a viral siRNA (vsiRNA) in HIV-1 
infected cells82 (Fig. 6). The viral siRNA derived from the Rev responsive element 
revvpu
tat
U5R RU3gag pol vif
vpr nefenv
miR-H1TAR miRNA
miR-N367vsiRNA
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(RRE) region within the env gene was detected with a specific probe by Northern blot 
analysis, showing a 21 nt long fragment not seen in uninfected cells. Consistent with 
its viral origin, the intensity of the 21 nt band increased over the course of HIV-1 
infection in T-cells. Overexpression of this viral siRNA significantly reduced env 
mRNA levels and viral replication. Furthermore, co-expression of 2’ O-methyl 
oligonucleotides complementary to the vsiRNA rescued env RNA expression. 
The TAR element in the LTR with its characteristic hairpin structure was reported to 
be cleaved by Dicer to generate viral miRNAs, miR-TAR-5p and miR-TAR-3p85,101 
(Fig. 6). MiR-TAR-3p seemed to be more abundant in HIV-1 infected cells103, and 
exhibited better suppression of HIV-1 gene expression85. However, both miRNAs 
might direct histone deacetylase HDAC-1 to the HIV-1 LTR promoter to silence 
transcription by chromatin remodelling101. Later, Klase and co-workers even 
proposed the omnipresent expression of TAR miRNA in all stages of infection, 
suggesting an anti-apoptotic function for infected cells103. Interestingly, a 124-mer 
TAR RNA domain present in HIV-2 is considered to possibly encode pre-miRNAs, 
and the resulting miRNAs may target a wide variety of cellular targets104. 
Another miRNA has been reported to be derived from a 81 nt structured region 
located immediately downstream of the 2 NF-kB sites in the LTR102, called miR-H1 
(Fig. 6). This miRNA supposedly has the ability to degrade the apoptosis 
antagonizing transcription factor (AATF) mRNA, resulting in downregulation of AATF 
gene expression and leading to cell death102. Furthermore, downregulation of AATF 
by miR-H1 was responsible for the suppression of genes coding for other proteins, 
including Dicer, as well as lower cell viability105. Additionally, mir-H1 seems to 
downregulate expression of cellular miRNA miR-149, which is considered to be able 
to target the HIV-1 vpr gene. Thus, the authors propose an epigenetic pathway 
responsible for the modulation of various cellular genes. In addition to those in vitro 
studies, miR-H1 variability in AIDS patients has been examined. A strong relationship 
between the miRNA sequence and the development of HIV-1-associated dementia 
(HAD) was detected106. 
Recently, various small noncoding RNAs with the length of miRNAs were discovered 
by ultra-deep sequencing, which are distributed over the whole HIV-1 genome107. A 
total of 47,773 clones were sequenced, of which 125 (0.3%) were HIV-1 specific 
sncRNAs. Especially a small 18 nt long RNA molecule, which is complementary to 
the HIV-1 primer binding-site (PBS), seemed to be highly abundant in productively 
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infected MT-4 T-cells. Supposedly, this small RNA is produced by Dicer cleavage of 
the HIV-1 PBS – tRNALys complex. Using immunoprecipitation, this small RNA was 
found to be associated with the Argonaute 2 (Ago2) protein, a central component of 
RISC. Together with the finding that this sncRNA led to a dose-dependent inhibition 
of virus production, this possibly suggests a function of this sncRNA in the RNA-
interference pathway targeting HIV-1. 
In contradiction to these reports, Pfeffer and colleagues detected only two viral 
sncRNAs in a total of 1,540 clones from HIV-1HXB2-Bru infected HeLa-T4+ cells80. 
However, no stable base-paired structures, that could display the potential precursor 
miRNAs, could be assigned to these HIV-1 specific sncRNAs and they were 
accordingly classified as degradation products by the authors80. Similarly, Lin and 
Cullen were not able confirm the existence of HIV-1 encoded miRNAs and siRNAs in 
T cell lines (MT-2, ACH-2) infected with HIV-1NL4-3 or the isolate QH0515 by Northern 
blot analysis and cDNA cloning98. However, the authors indicate that it may be 
possible for viral miRNAs to be present at very low levels (<0.5% of the total cellular 
miRNAs). It is very likely that expression of viral miRNAs vary between different cell 
types and different stages of infection. 
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1. Development of single copy sensitive qPCR for 
the detection of viral RNAs   
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Own contributions 
My major contributions to this study were in both the practical and the analytical part. 
I carried out the measurement of the signal to noise ratios (SNRs) and the melting 
temperature (Tm) of all 51 FH-probes. I also did the standard curves with the 
selected FH-probes over a range from 3 million to 0.3 copies per PCR to determine 
the 50% endpoint of PCR-positive dilutions as an indicator of assay-sensitivity. 
Additionally, I generated the melting profile of an overlapping 23-mer DNA and a 13-
mer DLNA (DNA locked nucleic acid) FH-probe, which confirmed that the DLNA FH-
probe showed indeed a higher thermal stability. I analyzed the data, performed the 
statistical analyses for determination of predictors of FH-probe performance, and 
wrote the manuscript. 
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Rational design of HIV-1 fluorescent hydrolysis probes 
considering phylogenetic variation and probe performance 
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Quantitative PCR (qPCR) using fluorescent hydrolysis probes (FH-probes; 
TaqMan®-probes) of variable genomes, such as HIV-1, can result in 
underestimation of viral copy numbers due to mismatches in the FH-probe’s 
target sequences. Therefore both target conservation and physical properties 
of FH-probes, such as melting temperature, baseline fluorescence and 
secondary structure, should be considered in design of FH-probes. 
Analysis of a database of 1242 near full-length HIV-1 sequences with a novel 
computational tool revealed that the probability of target and FH-probe identity 
decreases exponentially with FH-probe length. In addition, this algorithm 
allowed for identification of continuous sequence stretches of high 
conservation, from which FH-probes with global HIV-1 clade coverage could be 
chosen. To revise the prerequisites of physical FH-probe function, properties 
of 30 DNA and 21 chimeric DNA locked nucleic acid (DLNA) HIV-1 FH-probes 
were correlated with their performance in qPCR. This identified the presence of 
stable secondary structures within FH-probes and the base composition and 
thermal stability of the 5’-proximal end as novel predictors of FH-probe 
performance. 
Thus, empirically validated novel principles of FH-probe design regarding 
conservation and qPCR-performance were identified, which complement and 
extend current rules for FH-probe design. 
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Abbreviations 
Ct, cycle threshold; Delta-Tm, Tm-difference of FH-probe and the primer binding the 
same strand; DLNA, chimeric DNA locked nucleid acid; FH-probe, fluorescent 
hydrolysis probe; qPCR, quantitative PCR; RT-qPCR, reverse transcriptase qPCR; 
SNR, signal to noise ratio; Tm, melting temperature 
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1. Introduction 
Monitoring qPCR by FH-probes encounters its major pitfalls in assays examining 
phylogenetically diverse viruses such as HIV-1. While primers are relatively forgiving 
in respect to target variation1, as little as one mismatch in a FH-probe’s target 
sequence can greatly perturb the results of qPCR by underestimating copy 
numbers2. This feature of FH-probes is widely exploited in genotyping of single 
nucleotide polymorphisms3,4. 
Further factors influencing the function of FH-probes are related to their physical 
properties, which are determined by primary and secondary nucleic acid structure. 
Hybridization characteristics and kinetics of the FH-probe to its target have been 
assumed to be crucial for the performance of FH-probes. Hence, to ensure optimal 
binding of FH-probe to target, a choice of binding sites devoid of secondary 
structures and with 40-60% G/C content has been proposed5-9. In addition, to ensure 
hybridisation of the FH-probe before elongation of the newly synthesized DNA 
strand, it has been postulated that the melting temperature (Tm) of FH-probes should 
be 5-10°C higher than the Tm of the primer binding to the same DNA strand as the 
FH-probe5,6. 
Performance of FH-probes in qPCR assays also depends on intensity of 
fluorescence, which is suppressed in the absence of PCR target by a quenching 
moiety commonly placed at the 3’ end of the FH-probe and elicited by nucleolytic 
detachment of the base carrying the fluorophore, usually placed at the FH-probe’s 5’ 
end. The physical proximity of fluorophore and quencher in the absence of PCR 
product has been reported to influence performance of FH-probes9. Optimal proximity 
of the two modified bases in the free FH-probe may be attained by keeping the FH-
probe length minimal10 or, if long FH-probes need to be designed, by attachment of 
the quencher to internal positions11. 
Another important rule advises to avoid guanosine at the residue carrying the 
fluorophore because it quenches fluorescence even after hydrolysis and it may be 
cleaved off with reduced efficiency9,12. 
In the present study, the phylogenetic constraints for design of FH-probes were 
addressed by analyzing the relationship of FH-probe match frequency with FH-probe 
length and single base conservation. Physical properties of FH-probes and their 
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influence on FH-probe performance were examined by testing 51 probes targeting 6 
amplica (plural of amplicon) within the HIV-1 genome.  
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2. Methods 
2.1. Conservation of FH-probes 
The conservation of the chosen amplica was calculated by taking into account all 
circulating HIV-1 groups (subtypes M, N, O, CPZ). The sequences were obtained 
from curated alignments in the Los Alamos HIV Sequence Database (download 
2007, www.hiv.lanl.gov) comprising a total of 1242 sequences including 17% 
subtype-B isolates. Due to location at the ends of the genome, the early and the nef 
amplica, respectively, were only covered by 233 (34% subtype B) and 1231 (16.5% 
subtype B) viral isolates. The levels of single base conservation were compared to a 
global consensus and calculated using Bioedit13. 
Identification of short continuous stretches of matching oligonucleotide sequences 
was carried out using the R statistical computing environment (version 2.8.1)14 and 
tools from the seqinR package available at http://pbil.univ-lyon1.fr/software/SeqinR. 
Briefly, after removal of gaps, this implementation locates all possible substrings of a 
defined length within a reference sequence and calculates the corresponding 
frequencies of perfect matches to the alignment. Each amplicon was analyzed 
separately. The source code is available upon request.  
Match frequencies (Table 1) of FH-probes were calculated based for either only B-
subtypes or all HIV-1 groups (subtypes M, N, O, CPZ). 
 
2.2. FH-probe design 
All FH-probes contained the fluorophore FAM and the quencher TAMRA. Tms of the 
DNA FH-probes were calculated with an open source program (www.biophp.org) 
using the base-stacking algorithm, which was adjusted for the presence of 3mM 
MgCl2. In all FH-probes a 5’ terminal G was avoided5,6,8. The calculated Tms were 
aimed to exceed 55°C, except for mf341, which was designed solely based on 
phylogenetic considerations. DLNA FH-probes were designed with a length of 8-14 
bases and with a content of LNA bases of 10-75%. Tm for DLNA FH-probes was 
calculated with an open source program different from that used for DNA FH-probes 
(http://lna-tm.com), considering differences in melting temperature between DNA and 
LNA bases. 
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2.3. Tm measurement 
The Tm of the FH-probes was measured by examining the denaturation kinetics of 
the FH-probe (0.1uM) and its complementary strand (1uM) in a range from 30-90°C 
in 0.5°C intervals for 10 seconds using a real-time thermocycler (IQ5, Biorad, Basel, 
Switzerland). To attain conditions close to those of qPCR, the complementary 
strands were designed with overhangs of 3 bases avoiding dangling ends and the 
experiments were performed in 1 x Hotstartaq buffer (Qiagen) lacking enzyme with 
the inclusion of 3mM MgCl2. The analysis of the melting curves was executed by 
subtracting the background fluorescence of the FH-probe without the complementary 
strand from the fluorescence signal in reactions containing the complementary target. 
The Tm was defined as the temperature at which 50% of subtracted fluorescence 
was reached. 
 
2.4. PCR and signal to noise ratios 
DNA qPCR was performed as described previously15 using HotStarTaq Master Mix 
(Qiagen), 1uM of each primer and 0.1uM FH-probe. Experiments were done in 
duplicate using the real-time thermocycler IQ5 (BioRad, Basel) and as cycling profile: 
95°C 15’, 60x (95°C 5’’, 55°C 5’’, 60°C 40’’). The following primers were used; cr1 
(TCTCTGGCTAACTAGGGAACCCACTGCTT)16 and cr2 
(TGACTAAAAGGGTCTGAGGGATCTCTAGTTACCAG)16 for the early region, ts5’gag 
(CAAGCAGCCATGCAAATGTTAAAAGA)15 and skcc 
(TACTAGTAGTTCCTGCTATGTCACTTCC)17 for the gag region, mf209 
(AAAGCGTCTAGCCATGGCGTTAGTA) and mf302 (CAAATTTCTACTAATGCTTTTATTTTTTC) 
for the pol region, mf1 (CTTAGGCATCTCCTATGGCAGGAA)18 and mf238 
(GCTATTATTGCTGCTACTACTAATGCTACTA) for the tat region, mf222 
(GGCAGGGATATTCACCATTATCGTTTCAGA) and mf83 
(GGATCTGTCTCTGTCTCTCTCTCCACC)18  for the sa7 region, and mf345 
(AATCAGGGAAGTAGCCTTGTGT) and mf346 (GAGGTGGGTTTTCCAGT) for the nef region . 
HXB2 was chosen as a standard target for all the experiments and pHXB219 was 
linearized by digestion with Xho1. Concentration of the plasmid was quantified by 
spectrophotometry. Based on the length of the linearized plasmid (13000bp), the 
molecular weight (8.5x106 g/mol) and copy number were calculated. A standard 
dilution series with 10fold dilution steps was prepared. 
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SNRs of individual FH-probes were determined by amplification of constant copy 
numbers (3x106 copies HXB2 DNA) dividing mean fluorescence of the last 5 cycles 
of the amplification when fluorescence has reached a plateau, by mean fluorescence 
of the initial 5 PCR cycles. Means of two independent experiments using duplicate 
measurements were calculated.  
 
2.5. Calculations and Statistics 
Statistical analyses were performed either using GraphPad Prism5.0 software 
(GraphPad Software, San Diego, CA) or Stata (Version 10.0; StataCorp). 
Univariable and multivariable linear regression to determine predictors for SNRs of 
FH-probes were performed using Stata. P<0.05 was considered statistically 
significant. Factors with strong colinearity (p<0.01) were not included in the 
multivariable analysis. 
The following parameters were tested in univariable analyses additionally to the ones 
shown in Table 2, but without revealing statistically significant association with SNRs: 
G/C-basepairs in 1st and 2nd position, purine in 1st and 3rd position, concentration of 
the FH-probe, Tm of the primer binding the opposite strand as the FH-probe and 
distance of FH-probe to the primer binding the same strand as the FH-probe. 
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3. Results  
3.1. Phylogenetic complexity of conserved regions of the HIV-1 genome 
Amplica in 6 regions commonly used for HIV-1 qPCR due to their conservation or 
usefulness for monitoring important splice variants were assessed in this study: An 
amplicon mapping the primary viral transcripts in the R/U5 region (early), the coding 
region for p24-gag (gag), the start of the reverse transcriptase gene (pol), the first 
coding region of the tat-gene (tat), env-gp41 flanking the major splice acceptor 7 
(sa7) and the poly-purine tract within the nef gene (nef) (Table 1, Fig. 1a). 
Phylogenetic conservation within the six chosen amplica was analyzed with 
emphasis on match frequency, defined as 100% identity of FH-probe with its target, 
by employing a novel sequence scanning program. In this algorithm, a sequence 
defined as standard is screened in a sliding window approach for match frequencies 
of all possible FH-probes by comparison to a sequence database. In the present 
study, HXB2, the commonly used first molecular isolate of HIV-119, was used as the 
reference sequence and the database was a collection of 1242 near full-length HIV-1 
genome sequences representing phylogenetically distinct viral isolates spanning the 
full scope of the HIV-1 pandemic, which was extracted from the Los Alamos HIV 
Sequence Database (hiv.lanl.gov). Figure 1b shows an analysis of 10-, 20- and 40-
base oligomers plotted against average single base conservations. Theoretically, 
match frequencies (M) are proportional to the product of single base frequencies; this 
can be approximated by 
equation 1) M = (CGM) L, 
which potentiates the geometric mean of single base conservation (CGM) with 
oligonucleotide chain length (L).  
A comparison of calculated versus observed match frequencies revealed close 
correlation (Pearson r=0.96) but significantly higher values for observed match 
frequencies (Wilcoxon signed rank test, p<0.0001). The most likely explanation for 
this discrepancy is that single base conservations were not independent from each 
other but genetically linked due to constraints of codon usage and RNA structure. 
Thus, to adjust the model for linkage, a correction factor (λ) was introduced: 
Equation 2) M = (CGM) L × λ  
Fitting the dataset to equation 2 resulted in λ=0.74 (95% confidence interval: 0.73-
0.75). The model showed significant correlation (Pearson r=0.97) between observed  
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Table 1. Properties of FH-probes 
    positionC   match (%)D   TmF 
IDA FH-probe sequenceB amplica 5’ 3’ length all nonB B SNRE m p 
mf320 AAAGCTTGCCTTGAGTGCTTCA early 530 551 22 36 29 52 4.4 64.5 67.7 
mf321 TTCAAGTAGTGTGTGCCCGTCT early 548 569 22 36 29 49 3.8 64.5 68.9 
mf322 TGCCCGTCTGTTGTGTGACT early 561 580 20 64 50 92 6.6 63.5 69.1 
mf323 CCCGTCTGTTGTGTGACT early 563 580 18 64 50 92 5.9 57.5 64.3 
mf74 AGCACTCAAGGCAAGCTTTATTGAGGC 24 early 548 522 27 87 82 97 3.9 64 72.1 
ca20 TGtGtGCcCgT early 557 567 11 83 77 96 12.9 59 68 
ca21 TGtGtGccC early 557 565 9 95 92 100 9.9 57 64 
ca22 TGTGtGCCCGT early 557 567 11 83 77 96 10.5 52 56 
ca23 AGcTtGcCtTGaG early 532 544 13 96 95 97 10.7 62 67 
ca24 AGCttGCCttGaG early 532 544 13 96 95 97 27.3 62 70 
ca25 AGCtTGCCtTGAG early 532 544 13 96 95 97 8.2 53 54 
mf316 TAGAGTGCATCCAGTGCATGCA gag 1428 1449 22 0.8 0 4.8 5.8 65 68.7 
mf317 ATGCAGGGCCTATTGCACCA gag 1445 1464 20 22 16 51 6.5 63 68.8 
mf318 AGGCCAGATGAGAGAACCAAGG gag 1464 1485 22 24 15 65 4 69 68.9 
mf319 TGCAGCTTCCTCATTGATGGT gag 1419 1399 21 43 36 78 4.8 63 66.8 
Boe3 TCTATCCCATTCTGCAGCTTCCTCATT 25 gag 1431 1405 27 15 3.3 70 1.9 70.5 70.6 
Boe3.2 TCTATCCCATTCTGCAGCTTCCTCATTGATGG gag 1431 1400 32 13 2.8 66 1.7 73 74.3 
Boe3.3 TCCCATTCTGCAGCTTCCTCATTGATGG gag 1427 1400 28 38 32 69 2 56.3 73.5 
ri17 CCAtCaAtGaGGA gag 1400 1412 13 68 64 88 5 56 59 
ri18 CTGcAgAaTgGGA gag 1415 1427 13 80 78 86 1.3 62 66 
ri19 CATgCaGgGcCT gag 1444 1455 12 59 57 70 4.2 63 72 
ri20 AGGcCcTgc gag 1455 1447 9 79 77 90 5.9 58.5 61 
ri21 TCccattc gag 1427 1420 8 87 87 89 1.2 nn 53 
mf304 ATGGCCCAAAAGTTAAACAATGGCCA pol 2599 2624 26 22 13 67 4.9 66 71 
mf305 ATTCCTGGCTTTAATTTTACTGGTACAGT pol 2596 2568 29 47 41 76 2.2 66.5 68.2 
mf309 TTAAACAATGGCCATTGACAGAA pol 2611 2633 23 63 60 75 2.3 57 64.2 
mf348 AAGCCAGGAATGGATGGCC pol 2586 2604 19 63 60 81 8.5 65.5 67 
ri14 ACTgTaCcAgTA pol 2568 2579 12 83 81 91 1.6 54 54 
ri15 CAGgAaTgGaTGG pol 2590 2602 13 87 86 95 9.5 59 62 
ri16 CTGtCaAtGgCCA pol 2631 2619 13 82 81 90 9.3 63.5 64 
ri23 ATGgatgg pol 2595 2602 8 97 96 98 1.5 53 54 
mf82 TCTTCGTCGCTGTCTCCGCTTCTT 17 tat 6001 5978 24 17 7.6 64 2.5 61.5 72.7 
mf324 TCCCAACCCCGAGGGGA sa7 8386 8402 17 2.7 0.8 12 2.8 64.5 69.8 
mf325 CCCGAAGGAATAGAAGAAGA sa7 8412 8431 20 5.4 5.9 2.9 3.9 58.5 61.2 
mf326 CTCGGGGTTGGGAGGTG sa7 8398 8382 17 0.6 0 3.4 2.9 63.5 66.6 
mf327 CTATTCCTTCGGGCCTGTC sa7 8424 8406 19 5.5 6 2.9 4.4 63.5 64.4 
mf328 ACCCCGAGGGGACCC sa7 8391 8405 15 2.7 1.1 11 4 62 67.2 
mf2tq TTCCTTCGGGCCTGTCGGGTCCC 17 sa7 8421 8399 23 18 9.2 61 6.5 74.5 77.4 
mf226 AGGGGACCCGACAGGCCC 15 sa7 8397 8414 18 23 13 73 18.1 72 73.4 
ri10 TGTcGgGtCcCCTC sa7 8409 8396 14 32 24 74 3.8 73 75 
ri11 CCTgTcgGGtCCC sa7 8411 8399 13 38 29 79 3.2 59 73 
ri12 CCCgACaGgCcCG sa7 8403 8415 13 36 28 77 3.9 64 77 
ri13 CGAcAgGcCCgAA sa7 8405 8417 13 31 24 69 4.3 58 76 
ri22 CGAcAggC sa7 8405 8412 8 75 73 87 1.4 53 55 
mf342 TTTTTAAAAGAAAAGGGGGGAC nef 9064 9085 22 86 88 77 1.1 66.5 62.3 
mf343 AAGAAAAGGGGGGACTGGA nef 9071 9089 19 87 89 77 1.3 63 65.5 
mf344 ACAGATCAAGGATATCTTGTCT nef 9133 9112 22 8 2.4 36 1.7 54 61.4 
mf341 CTTTTTAAAAGAAAAGGGG nef 9063 9081 19 83 86 70 1 42 54.5 
ca18 CAAGGCAGCTGTAGATCTTAGCCA nef 9039 9062 24 3.4 0.5 18 3.8 63 68.8 
ca19 AGGGCTAATTCACTCCCAACGA nef 9090 9111 22 0.2 0.1 0.5 9.3 63 68.5 
ca26 AGGGGgGaCtGgA nef 9077 9089 13 95 95 95 4.2 58 74 
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A ID denominates identification of FH-probes according to internal nomenclature in the 
author’s laboratory. 
B Sequence of the FH-probe (5’ to 3’): capital letters indicate DNA bases and lower case 
letters indicate LNA bases. 
C Numbering based on the HXB2 genome according to the software provided by the Los 
Alamos HIV Sequence Database (SEQUENCE LOCATOR, www.hiv.lanl.gov). 
D Conservation of all subtypes (all), nonB- (nonB) or B-subtypes (B) was calculated by 
comparison to sequences that were obtained from curated alignments in the Los Alamos HIV 
Sequence Database (download 2007, www.hiv.lanl.gov). 
E Signal to noise ratio 
F Measured (m) and predicted (p) melting temperature (Tm) (°C) 
 
 
 
and predicted match frequency and no significant difference between them (Wilcoxon 
signed rank test, p=0.32). This analysis demonstrates that the probability that an 
oligonucleotide will find its match in a viral population decreases exponentially with 
FH-probe length (Fig. 1c).  The influence of the oligonucleotide length may be 
relieved if genetic linkage results in coinheritance of clusters of bases, in which case, 
λ<1, oligonucleotide length is virtually shortened.  
In contrast to these constraints related to assay sensitivity, specificity of FH-probe 
binding (S), defined as the probability that a certain sequence would not occur in a 
random amplicon, can be approximated by 
equation 3) S = (1-(1/4)L) (A-L+1) ,  
where L is the length of the FH-probe and A the length of a random, erroneously 
amplified sequence. This equation can be justified as follows: The probability, that 
the FH-probe matches a given stretch of length L (i.e. the length of the FH-probe) is 
(1/4)L (assuming equilibrium of all 4 bases). The entire amplicon can be viewed as 
consisting of A-L+1 stretches of length L. This approximation further assumes that 
the event of matching a given stretch is independent from matching the other 
stretches. Under this assumption the probability of obtaining no match at all is (1-
(1/4)L) (A-L+1). Thus, it was estimated that the specificity of FH-probe binding exceeds 
99% with a FH-probe length of >9bases and A ranging from 40-1000 bases (Fig. 1c). 
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Figure 1. Phylogenetic complexity of conserved regions of the HIV-1 genome.(a) FH-
probes mapping to 6 regions of the HIV-1 genome were designed utilizing the HXB2 
sequence as a template. Upper panel: Small arrows mark the location of amplica in the viral 
genome. Lower panel: Conservation of the chosen amplica among all circulating HIV-1 
clades (subtypes A-O, sequences obtained from curated alignments in the Los Alamos HIV 
Sequence Database, download 2007, www.hiv.lanl.gov). The colored area shows the level of 
single base conservation as compared to a global consensus sequence, and grey bars 
signify the conservation of the actual HXB2-sequence when this deviates from consensus. 
(b) Dependence of match frequencies of oligonucleotides on base conservation and 
oligonucleotide-length (L). HIV-1 sequence alignments were scanned for the presence of all 
possible 10- (red, yellow), 20- (magenta), and 40-mers (black) in the 6 chosen amplica. 
Match frequencies (M) were plotted against average (GM, geometric mean) of single base 
conservation (C). Broken lines show prediction of M by equation 1) M = (CGM) L. Steady lines 
depict predictions by equation 2) M= (CGM) Lx λ including a correction factor (λ) to account for 
linkage. Brown lines show predictions for 10-mers, magenta lines for 20-mers and black lines 
for 40-mers. (c) Calculated match frequencies (M according to equation 2) (left y-axis; red 
circles, error bars: 95% confidence intervals, shaded area: range). Specificity (S, right y-axis) 
of FH-probe binding is modelled as a function of FH-probe length (L) and length of an 
erroneously produced amplicon (A): Equation 3) S = (1-(1/4)L) (A-L+1) (A=40 bases: blue 
crosses, A=100 bases: blue diamonds, A=1000 bases: blue asterisks)  
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3.2. Signal to noise ratios of FH-probes as indicators of DNA FH-probe 
performance 
In previous studies signal to noise ratios (SNRs) of fluorescent probes were used to 
gauge efficacy of qPCR assays20,21. To confirm this concept, SNRs of individual FH-
probes were calculated by dividing fluorescence at the end of the amplification by 
fluorescence during the initial cycles of amplification. To avoid interference of qPCR 
by possible primer dimer amplification and the resulting reduction of fluorescence in 
reactions with low copy numbers22, high amounts of template (3x106 copies HXB2 
DNA) were used. As shown in Figure 2a and Table 1, performance in a panel of 30 
DNA-based FH-probes ranged from ineffective (mf342, SNR=1.1) to excellent 
(mf226, SNR=18.7). Cycle threshold (Ct) -values and their standard deviations, 
respectively, showed significant inverse correlation with SNRs (Pearson r=-0.52; 
p=0.004 and r=-0.59; p=0.0007 respectively), confirming association of SNRs with 
sensitivity and reproducibility of qPCR. 
 
3.3. Predictors of SNRs of DNA FH-probes 
To assess the factors influencing biochemical performance of the DNA FH-probes, 
SNRs and their different potential predictors were examined in univariable and 
multivariable linear regression models (Table 2). Melting temperature (Tm) showed 
weak but significant correlation to SNRs, either when measured or predicted by 
nearest neighbour analysis (p=0.033; measured and p=0.038; predicted). High G/C 
content of the DNA FH-probe was associated (p=0.002) with high SNRs. 
Furthermore, the presence of G/C rich secondary structures within the FH-probe 
was, in contradiction to current rules, a highly significant positive predictor of SNRs 
(p<0.001). FH-probes with intramolecular stem-loop structure containing one or more 
G/C base-pairs performed better than FH-probes with no or only a weak secondary 
structure (Fig. 2b, p=0.003). A trend for association of short FH-probe length 
(p=0.102) with high SNRs was observed, while Tm-difference of FH-probe and the 
primer binding the same strand (Delta-Tm) lacked correlation (p=0.742). 
Upon encountering FH-probe bound to its template, taq polymerase can either 
remove the FH-probe by exonucleolytic cleavage or by strand displacement. We 
hypothesized that stability of the probe-template complex at its 5’ end may favour 
exonucleolytic cleavage and generation of free, unquenched fluorophore. Thus, 
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thermal stability and base composition of the 5’ ends of the FH-probes were analyzed 
in detail. 
SNRs were positively associated with the predicted Tm of the ten 5’ proximal bases 
(Pearson r=0.65, p=0.0001) (Fig. 2c). In agreement, FH-probes with a G or C at 
position 3 showed significantly elevated SNRs as compared to those with A or T 
(p=0.001, data not shown). At the second position, presence of G was favourable, 
followed by presence of A. Hence, SNRs of DNA FH-probes with a purine at position 
two were significantly higher than SNRs with a pyrimidine (Fig. 2d, p=0.01). No 
significant association of the bases at the first position with SNRs was observed. 
Multivariable analysis, including statistically significant factors (p≤0.05 in univariable 
analysis), except for those with strong colinearity (p<0.01), resulted in a model in 
which 5’-proximal Tm (p=0.006), a purine at position 2 (p=0.035) and the numbers of 
intramolecular G/C-basepairs (p=0.004), explained 67% of the variability in SNRs 
(Table 2). 
Thus, we suggest the following rules to design functional DNA FH-probes: 5’-
proximal Tm ≥ 30°C, a purine at position 2 and ≥ 2 intramolecular G/C-basepairs. 
 
Figure 2. Performance of DNA FH-probes and analysis of predictors of SNRs. (a) 
Amplification curves of DNA FH-probes in 6 amplica (n=1-7, see Table 1). Fluorescence at 
each cycle was normalized to the baseline fluorescence of the first 5 cycles. Dotted lines 
indicate baseline fluorescence. (b) Comparison of SNRs of DNA FH-probes containing <1 
(diamonds) or 0-1 G/C (triangles) base-pairs in a stem-loop. (c) Pearson correlation analysis 
of the Tm of the 5’ proximal 10 bases of the DNA FH-probes with SNRs. (d) Comparison of 
DNA FH-probes containing a purine (circles) or a pyrimidine (triangles) at the 2nd position. P-
values in (b) and (d) were calculated by Mann Whitney testing. 
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3.4. Performance of DNA FH-probes in qPCR 
Four FH-probes with SNR>2 were chosen for further analysis according to their 
phylogenetic match frequencies: mf74 within early (87% match to viral isolates from 
all clades, 97.5% clade B), mf319 in gag (42% overall, 77.5% clade B), mf348 in pol 
(63% overall, 81% clade B), and mf226 in sa7 (22.8% overall, 72.6% clade B). FH-
probes within nef and tat were not included due to low match frequencies within the 
set of utilizable FH-probes (<20%). HIV-1 DNA copies were measured by qPCR in a 
range from 3 million to 0.3 copies per PCR and the 50% endpoint of PCR-positive 
dilutions was determined as an indicator of assay-sensitivity. All qPCRs using gag, 
pol and sa7 FH-probes reached single copy sensitivity (Fig. 3b-d), while amplification 
of the early amplicon showed slightly reduced sensitivity presumably due to formation 
of primer dimers in later cycles (Fig. 3a), typically resulting in progressive diminution 
of signal amplitudes15. 
Thus, quantification of HIV-1 DNA was achieved over 6 orders of magnitude 
approaching single copy sensitivity for 3 FH-probes. Although they matched B-
subtypes with reasonable frequency, match frequencies for nonB-subtypes were 
insufficient to cover the full scope of the global pandemic. 
 
3.5. Improved short FH-probes using locked nucleic acid analogues 
To design FH-probes with higher clade coverage, shorter chimeric DNA locked 
nucleic acid (DLNA) FH-probes were used. In locked nucleic acids base pairing is 
stabilized by a 2-O,4-C-methylene bridge on the ribose moiety23. As exemplified in 
Figure 4a, a 13-mer DLNA FH-probe showed higher thermal stability when bound to 
its complementary strand than an overlapping 23mer DNA FH-probe. 
To identify candidate short FH-probes with high conservation, the sequence scanning 
algorithm was employed. An example is shown for the pol amplicon (Fig. 4b), which 
was scanned for all possible 8-, 10-, 12- and 14-mers. This procedure identified 
separate peaks of highly conserved sequence stretches from which FH-probes were 
chosen. Based on this analysis, 21 DLNA FH-probes (6 in early, 5 in gag, 4 in pol, 5 
in sa7, 1 in nef, Table 1) ranging from 8-14 bases were synthesized. 
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Figure 3. Sensitivity of qPCR using selected DNA FH-probes. DNA FH-probes with 
SNRs > 2 and the highest phylogenetic match frequencies of HIV-1 in each amplicon were 
used for amplification of HXB2 DNA in a range from 3 million to 0.3 copies per PCR. Broken 
vertical lines show the 50% endpoint of PCR-positive dilutions and thus signify sensitivity of 
the assays. qPCR for gag (b), pol (c) and sa7 (d) reached single copy sensitivity, while 
amplification of the early (a) amplicon showed reduced sensitivity presumably due to primer 
dimer formation. Experiments were performed in duplicate (3x106-3x103 copies) or 
quadruplicate reactions (<3x103 copies). Results of linear regression of log10 of DNA copy 
numbers versus Ct-values are depicted. Inserts show amplification plots of PCR-cycle (x-
axis) versus baseline subtracted fluorescence (y-axis), with dotted lines displaying the 
fluorescence threshold and grey symbols showing negative controls. 
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3.6. Predictors of SNRs of DLNA FH-probes 
SNRs of DLNA FH-probes were measured as described for DNA FH-probes. Ct-
values and their standard deviations, respectively, were inversely correlated with 
SNRs (Pearson r=-0.55; p=0.01 and Pearson r=-0.73; p=0.0003). 
SNRs of DLNAs were tested for association with Tm, FH-probe length, G or C at 
position 3 and purine at position 2. Intramolecular G/C-basepairs were not assessed 
because DLNA FH-probes generally contained no secondary structures. Similarly, 
the Tm of the ten 5’ proximal residues was not assessed as it was virtually identical 
to overall Tm. Finally, to account for the fact that not only G/C-residues promote 
strong basepairing but also LNA-residues, the presence of weakly pairing bases 
(plain A/T content, i.e. no G/C no LNA) was assessed rather than presence of 
strongly pairing bases (G/C, LNA). 
The sole statistically significant predictor identified in univariable analysis was purine 
at position 2 (p=0.009). For identification of additional potential predictors, inclusion in 
the multivariable model was extended to parameters with a univariable p-value ≤0.1. 
This resulted in a model explaining 56% of the data variability (Table 2), in which 
purine at position 2 (p=0.007) and FH-probe length (p=0.023) positively predicted 
SNRs, while plain A/T-content showed a negative association (p=0.040). 
Thus, we propose the following rules to design functional DLNA FH-probes: A purine 
at position 2, length ≥ 11 nucleotides and a plain A/T-content ≤ 35%. 
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Table 2. Predictors of SNRs of DNA and DLNA FH-probes 
    Univariate analyses   Multivariate analyses  
    Coefficient (95% CI) p  Coefficient (95% CI) p r2 
DNA Tm measured (°C)A 0.018 (0.001; 0.03) 0.038  0.005 (-0.01; 0.02) 0.356 0.68
(n=30) G/C content (%)B 0.013 (0.005; 0.02) 0.002    
 FH-probe length -0.022 (-0.05; 0.005) 0.102     
 Predicted Tm 5’ end (°C)C 0.025 (0.01; 0.04) <0.0001  0.015 (0.005; 0.03) 0.006  
 G/C-basepair in 3rd position 0.331 (0.14; 0.52) 0.001    
 Purine in 2nd position 0.27 (0.07; 0.47) 0.01  0.155 (0.01; 0.30) 0.035  
 Delta-Tm (°C)D 0.003 (-0.01; 0.02) 0.742    
  Intramolecular G/C-basepairs  0.12 (0.06; 0.17) <0.0001  0.074 (0.03; 0.12) 0.004   
DLNA Tm measured (°C)A 0.011 (-0.02; 0.05) 0.53       0.56
(n=21) Plain AT-content (%)E -0.014 (-0.03; 0.002) 0.091 -0.014 (-0.03;-0.001) 0.04  
 FH-probe length 0.068 (-0.02; 0.15) 0.107 0.077 (0.01; 0.14) 0.023  
 G/C-basepair in 3rd position 0.044 (-0.31; 0.40) 0.797    
 Purine in 2nd position 0.423 (0.12; 0.73) 0.009 0.377 (0.12; 0.64) 0.007  
  Delta-Tm (°C) D -0.009 (-0.03; 0.02) 0.453         
 
A Measured melting temperature.B Content (%) of G and C bases.C Predicted melting 
temperature of the 10 proximal bases at the 5’ end. D Difference between the Tm of the FH-
probe and the Tm of the primer binding the same strand as the FH-probe. E Content (%) of A 
and T bases, not including LNA bases 
 
 
 
 
Figure 4. Melting profiles and match frequencies of DLNA FH-probes. (a) Melting 
profiles of two FH-probes within pol. The 13-mer DLNA FH-probe ri16 is depicted in blue and 
the overlapping 23-mer DNA FH-probe mf309 in grey. Symbols connected by lines show 
relative fluorescence and plain lines show their first derivatives. (b) Matching of HXB2 
derived 8-, 10-, 12- and 14-mers to the aligned HIV-1 sequences of the Los Alamos HIV 
Sequence Database (download 2007, www.hiv.lanl.gov) starting at the indicated position 
within the pol amplicon (position 2500 to 2630, HIV-1 HXB2, GenBank accession number 
K03455). 
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3.7. Performance of DLNA FH-probes in qPCR 
Based on their SNRs and phylogenetic conservation, DLNA FH-probes representing 
gag (ri20, 79% match to viral isolates from all clades, 90% in subtype B), sa7 (ri12, 
overall 36%, subtype B 77%), nef (ca26, 95% overall and for clade B) and 2 FH-
probes for pol (ri15, 87% overall, 94% clade B and ri16, 82% overall, 90% clade B) 
were further tested for their usefulness in qPCR (Fig. 5). FH-probes for the early 
amplicon were not included in this analysis because of the slightly reduced sensitivity 
of the qPCR, as shown above for DNA FH-probes, and because the dataset for this 
amplicon compassed a smaller number of viral variants than the other amplica 
(n=233 versus n=1242) with overrepresentation of subtype B (34% versus 17%). All 
PCR assays ranged over 6 orders of magnitude and reached single copy sensitivity. 
In a previous study match frequencies of an RT-qPCR assay were boosted by adding 
two FH-probes into a single reaction18. The rationale was that fluorescence is 
expected to show up when at least one of two FH-probes A and B fits its target. This 
combined match frequency (MAvB) can be estimated as 
equation 4) MAvB = MA + MB - (MA x MB). 
This concept was employed with 2 FH-probes in pol (ri15 and ri16), which resulted in 
qPCR with single copy sensitivity (Fig. 5d). Assays performed with single FH-probes 
gave indistinguishable results (data not shown). Combinatorial analysis as described 
by equation 4, predicted that 97.8% (observed 96.7%) of viral isolates among all 
clades and 99.4% (observed 99.0%) within clade B, would match at least one of 
these two FH-probes. Thus, combination of two pol FH-probes resulted in near-
universal clade coverage. 
The nef DLNA FH-probe (ca26) showed the highest match frequency (95%) and 
good performance in DNA assays. However, when it was employed for RNA in one-
step RT-qPCR under less stringent conditions (annealing at 50°C for 30 minutes), 
false positive reactions were observed at low frequencies presumably due to the 
stretch of 6 guanosines in a row. The other 4 DLNA FH-probes in this subset 
functioned reproducibly, with great specificity and without giving rise to false positive 
results using uninfected human PBMC DNA as a template, as well as in RT-qPCR 
(unpublished results). 
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Figure 5. Sensitivity of qPCR using selected DLNA FH-probes. DLNA FH-probes with 
SNRs > 2 and the highest phylogenetic match frequencies of HIV-1 in each amplicon were 
used for amplification of HXB2 DNA in a range from 3 million to 0.3 copies per PCR. Broken 
vertical lines show 50% endpoints of PCR-positive dilutions and thus signify sensitivity of the 
assays. All qPCRs using gag (a), sa7 (b), and nef (c) DLNA FH-probes reached single copy 
sensitivity. Two pol FH-probes that had both reached single copy sensitivity in qPCR on their 
own, were combined in one qPCR (d). This assay also reached single copy sensitivity. 
Experiments were performed in duplicate (3x106-3x103 copies) or quadruplicate reactions 
(<3x103 copies). Results of linear regression of log10 of DNA copy numbers versus Ct-values 
are depicted. 
Inserts show amplification plots of PCR-cycle (x-axis) versus baseline subtracted 
fluorescence (y-axis), with dotted lines displaying the fluorescence threshold and grey 
symbols showing negative controls. 
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4. Discussion  
In the present study, both the structural as well as the phylogenetic side of FH-probe 
design for HIV-1, a paradigm for a virus with high genetic diversity, were addressed. 
In consideration of the finding that match frequencies decrease exponentially with 
sequence length, usage of short optimally conserved FH-probes was aimed for. This 
has been facilitated by a novel computational tool to systematically identify stretches 
of highly conserved regions to which FH-probes may be targeted. This and the 
availability of locked nucleic acid analogues enabled us to design short FH-probes 
matching up to 95% of a representative collection HIV-1 isolates. Similarly, by 
combining two FH-probes within the same reaction, phylogenetic coverage could 
even be increased to 97%. 
Regarding performance of FH-probes, analysis of the dataset in this study allowed to 
determine rules empirically for FH-probe design with the limitation that the collection 
of FH-probes was not strictly random and that certain rules were initially followed in 
design of FH-probes.  
In agreement with current rules6, a significant impact of stability of the probe-target 
complex both on DNA as well as on DLNA FH-probes was observed. However, more 
than the Tm, representing overall stability, the local stability near the site of 
nucleolytic cleavage of the FH-probe appeared to exert a marked influence on FH-
probe performance. Hence, the Tm of the first 10 5’-proximal bases was a significant 
positive predictor of the SNRs.  Moreover, stabilization of the probe-target duplex 
appeared to be mediated by forces beyond mere Watson Crick basepairing, as 
indicated by the observation that a purine at position 2 significantly predicted SNRs in 
the two independent datasets comprising DNA and DLNA FH-probes. This finding 
may reflect hydrophobic interaction of the FH-probe fluorophore with the extensive 
hydrophobic structure of the purine-rings. 
Paradoxically, presence of intramolecular G/C base-pairs within DNA FH-probes was 
significantly associated with high SNRs despite their potential to compete with 
hybridization to the target strands. In analogy to molecular beacon probes which rely 
on stem-loops bringing fluorophore and quencher in juxtaposition24, intramolecular 
G/C base-pairs in FH-probes may increase quenching in the absence of target. In 
agreement, significant correlation of intramolecular G/C base-pairs with baseline 
fluorescence (data not shown, Pearson r=-0.53, p=0.003) was observed. 
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Similarly to DNA FH-probes, the three identified predictors of DLNA FH-probe 
performance, purine 2, chain-length and low content of plain A/T base-pairs, all may 
influence duplex-stability. The fact that the Tm appeared not to predict FH-probe 
performance can be interpreted as a consequence of sampling, since DLNA FH-
probes were chosen to exceed, whenever possible, a predicted Tm of 55°C in order 
to have a chance to perform well. 
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5. Conclusions 
In summary, the following empirically tested positive predictors of biochemical FH-
probe performance emerged from this study: 
1. A purine at position 2 (DNA and DLNA). 
2. An overall Tm ≥ 60°C and Tm of the first ten 5’ proximal bases ≥ 30°C (DNA). 
3. Presence of G/C rich (≥ 2 G/C-basepairs) secondary structures (DNA). 
4. Sequence length (≥ 11) and low contents (≤ 35%) of plain A/T bases (DLNA). 
Moreover, within the set of well performing FH-probes, application of the algorithm to 
scan sequence databases for FH-probes with optimal phylogenetic conservation, 
allowed to identify functional FH-probes in various regions of the HIV-1 genome 
approaching coverage of the global HIV-1 pandemic. It is conceivable that application 
of these phylogenetic and biochemical principles for FH-probe design may also be 
extended to other phylogenetically diverse biological systems. 
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Own contributions 
My major contributions to this study were as follows: I performed experiments to 
establish and apply the hybridization capture method for the enrichment of sncRNAs. 
I established HIV-1 sncRNA specific PCRs to investigate the presence of HIV-1 
derived sncRNAs in infection experiments with the primary virus isolates, which I 
used to infect PBMC from different HIV-1 negative blood donors. Furthermore, I 
sequenced some exemplary PCR products to confirm the presence of HIV-1 
sncRNAs in various virus isolates. I processed all raw sequence data of all libraries 
and analyzed the resulting small noncoding RNAs (sncRNAs). In particular, this 
included the performance of alignments to determine sequences with >90% 
homology to HIV-1, and the determination of unique HIV-1 sncRNAs which are 
derived from a different library, and/or are differing in length and/or position. I also 
carried out the analysis of the non HIV-1 clones to group them to different classes of 
cellular small noncoding RNAs. Additionally, I characterized the single unique HIV-1 
sncRNAs according to their length and secondary structure. I performed all statistical 
analyses and wrote the manuscript. 
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Novel targeted enrichment strategy enables detection of 
low abundant small noncoding RNAs in HIV-1 infection 
 
 
Claudia F. Althaus1,3, Valentina Vongrad1,3, Barbara Niederöst1, Beda Joos1, 
Francesca Di Giallonardo1, Philip Rieder1, Jovan Pavlovic2, Alexandra Trkola2, 
Huldrych F. Günthard1,4, Karin J. Metzner1,4 & Marek Fischer1,4 
 
 
1Division of Infectious Diseases, University Hospital Zurich, University of Zurich, 
Switzerland; 2Institute of Medical Virology, University of Zurich, Switzerland; 3These 
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This article is dedicated to the memory of Marek Fischer, who died in December 
2010. 
 
The various classes of small noncoding RNAs (sncRNAs) are important 
regulators of gene expression. While a rapidly increasing number of sncRNAs 
has been identified over recent years, isolation of sncRNAs of low abundance 
remains challenging. Virally encoded sncRNAs can be expressed at very low 
levels. This is best illustrated by HIV-1 where virus encoded sncRNAs 
represent at the outmost 0.1-0.5% of all sncRNAs. Here we report on a novel, 
sequence targeted enrichment strategy which allows a greater than 100-fold 
enrichment of low abundant sncRNAs. Using HIV-1 as model system, we 
generated sncRNA libraries from HIV-1 infected cells, which led to 892 
individual HIV-1 sncRNA clones representing more than 70% of all sncRNA 
clones identified. This enormous capacity to enrich low abundance sncRNAs in 
a sequence specific manner highly recommends our selection strategy for any 
type of investigation where origin or target sequence of the sought-after 
sncRNAs are known. 
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Introduction 
 
One major posttranscriptional regulatory pathway, RNA interference (RNAi), is 
mediated by small noncoding RNAs (sncRNAs)1. Over recent years, the importance 
of the diverse classes of sncRNAs has been widely recognized and their impact on 
various biological processes demonstrated across a broad variety of organisms2. The 
most intensively studied class of sncRNAs are the 20-25 nucleotides long 
microRNAs (miRNAs) which play a crucial role in posttranscriptional regulation of 
gene expression3. 
 
Despite technological advances sncRNAs of low abundance have remained difficult 
to identify. Until to date, the most frequently employed method to derive sncRNAs is 
the generation of cDNA libraries encoding sncRNAs by, rather rate limiting, cloning 
and sequencing procedures4. More recently, high-throughput sequencing techniques 
have been applied5,6. While these techniques allow the identification of sncRNAs of 
medium to high frequency with notable success, they remain less effective in defining 
low abundant sncRNAs. Alternate approaches have employed microarray- and PCR-
based technologies to detect and quantify sncRNAs4,7. However, due to the short 
length of oligonucleotides used in microarrays and the target specificity of PCR, 
these procedures only lend themselves towards analyses where already known or 
predicted sncRNAs need to be detected. 
 
Discovery and screening for viral sncRNAs in infected cells faces two challenges: 
Firstly, sequence and length of these viral sncRNAs are yet unknown excluding 
approaches which depend on target specific amplification. Secondly, depending on 
the virus studied, virus-encoded sncRNAs may be of extremely low abundance. The 
first discovery of viral miRNAs was made in Epstein-Barr virus (EBV)-infected human 
cell lines8 where 4.15% sncRNAs of EBV origin were identified. The specificity could 
be enhanced by employing subtractive hybridization which yielded libraries consisting 
of ~40% EBV derived sncRNAs9. A similar high abundance of viral sncRNAs was 
also observed in cells infected with other DNA viruses10. However, sncRNAs from 
RNA viruses have thus far proven less frequent, accounting commonly for <1% of all 
sncRNAs in infected cells11. 
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HIV-1 generates sncRNAs in very low abundance10,12, if at all13. So far, only four 
sncRNAs with miRNA-like functionality have been identified in HIV-1 infected cells 
and mapped to domains in TAR14,15, env16, nef17 and U318. The first published report 
on screening for sncRNAs in HIV-1 infected cells detected only two viral sncRNAs in 
1,540 clones from HIV-1 infected HeLa T4+ cells (0.13%). No functional property 
could be assigned to these HIV-1 sncRNAs and they were accordingly classified as 
degradation products by the authors10. Another study screened 600 sncRNA clones 
derived from HIV-1 infected cells for HIV-1 sncRNAs but found none which contained 
a viral sequence13. More recently, two independent surveys performed high-
throughput sequencing of HIV-1 infected cell libraries and detected 0.26%12 and 
0.50% (Schopman, N., Bradley, T., Willemse, M., van Kampen, A., Baas, F., 
Berkhout, B., Haasnoot, J., Keystone Symposia, Whistler, Canada, 20-25 March 
2011, abstract #418) HIV-1 sncRNAs in approximately 48,000 and 5.2 million 
screened sncRNAs, respectively. 
 
As these studies highlight, identification of low abundant sncRNAs, such as HIV-1 
encoded sncRNAs, requires either screening of a large number of sequences or an 
optimized selection protocol. Here we report on a novel selection and enrichment 
strategy for low abundant sncRNAs. Key to this approach is a highly effective 
enrichment by hybridization capture where hybridization probes covering the entire 
genome of the organism of interest - in our case HIV-1 - are included. This approach 
is highly successful in detecting low abundant HIV-1 sncRNAs in cDNA libraries 
obtained from HIV-1 infected primary human cells. The yield of HIV-1 sncRNAs 
increased from previously reported 0.1-0.5% to an average of 78.3% (±7.6% (SD)) of 
total sncRNAs in several independent libraries allowing for the first time a non-biased 
evaluation of the regulatory properties of HIV-1 sncRNAs during the course of the 
infection.  
 
Our novel approach to enrich for low abundant sncRNAs is highly effective and can 
easily be adapted to other model organisms or genomic regions of interests where an 
analysis of the complete spectrum of low and high abundant sncRNAs is warranted 
for.  
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Results 
 
Enrichment and selection of low abundant HIV-1 sncRNAs by hybridization 
capture 
The overall aim of our study was to derive an effective selection strategy for low 
abundant sncRNAs which would allow 1) to determine the presence or absence of 
sncRNAs in a given setting and 2) allow the characterization of the full spectrum of 
sncRNAs generated by a specific organism. Our model organism was HIV-1 where 
conflicting reports have been published which suggested that either no or only 
extremely low numbers of HIV-1 sncRNAs are evolved in infected cells. Our intent 
was foremost to derive a protocol that allows sufficient enrichment of low abundant 
sncRNAs. As outlined in the following, we achieved this by introducing a specific 
selection step which enriched for HIV-1 derived sequences. Figure 1 illustrates the 
various steps involved in our sncRNA selection procedure. To generate sncRNA 
libraries we first infected human primary cells (either CD4+ T-lymphocytes or 
macrophages) with the HIV-1 isolate JR-FL (Fig. 1, Step 1). Seven to 14 days post 
infection, when a sufficient degree of infection of the cultures was reached as judged 
by p24 antigen production, small RNA species (<200 nt) were extracted from the 
infected cultures using a commercially available extraction procedure (Fig. 1, Step 2). 
Derived small RNAs where then subjected to C-tailing of the 3’-end and adaptor 
ligation at the 5’-end (Fig. 1, Step 3). To generate a cDNA library, RNA was reverse 
transcribed and cDNA amplified by PCR (Fig.1, Step 4). The next step was key for 
the success of our procedure as we here enriched for HIV-1 encoded sncRNAs by 
specifically selecting HIV-1 sncRNAs which bound to single-stranded HIV-1 DNA in a 
hybridization step (Fig.1, Step 5). The HIV-1 ssDNA hybridization probes used for 
this purpose were generated from proviral DNA of HIV-1JR-FL by PCR. In total, five 
probes covering the entire HIV-1 genome were generated (Fig. 1, Box 1). The 
primers used to amplify those hybridization probes were biotinylated which allowed to 
couple the derived probes to streptavidin beads. Adaptor-ligated cDNA derived in 
Step 4 was then hybridized to the HIV-1 ssDNA hybridization probes, followed by a 
magnetic bead purification step to eliminate nonhybridized cDNA species (Fig. 1, 
Step 5). The five HIV-1 ssDNA hybridization probes were either used together (as 
shown in Fig.1, Step 5) or in separate reactions. Both approaches proved equally  
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Figure 1. Scheme of cDNA library generation with hybridization capture for HIV-1 encoded 
small noncoding RNAs (sncRNAs). Primary human cells (macrophages or CD4+ T-
Lymphocytes) were infected with HIV-1JR-FL (Step 1). Cellular (black) and HIV-1 encoded 
(bright green) sncRNAs (<200 nt) were extracted from primary HIV-1 infected cells (Step 2). 
RNA was C-tailed at the 3’-end, adaptor-ligated at the 5’-end (Step 3) and RT-PCR was 
performed (Step 4). For the preparation of the HIV-1 ssDNA hybridization probes, PCR was 
performed with biotinylated primers for 5 overlapping regions of the genome using HIV-1JR-FL 
plasmid as template. Biotinylated amplicons were attached to streptavidin beads (Box 1). 
Sequences homologous to HIV-1 were enriched by incubation of cDNA derived from 
adaptor-ligated sncRNAs with a mixture of the 5 different HIV-1 ssDNA hybridization probes 
(Step 5); alternatively each HIV-1 ssDNA hybridization probe was used separately. After 
hybridization capture, bound amplicons were eluted, amplified and size selected on a gel 
(Step 6). Either the hybridization and size selection steps were repeated (Step 7) or the 
amplicons were directly cloned and sequenced after one round of selection (Step 8).  
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effective. Bead enriched cDNA was then dehybridized, amplified by PCR and 
additionally size selected (Fig. 1, Step 6) before undergoing either a further round of 
hybridization selection (Fig. 1, Step 7) or cloning into vector DNA and sequence 
analysis (Fig. 1, Step 8). 
 
We successfully employed this procedure, performing one round of selection, for two 
independent cDNA libraries which yielded 4.8% and 12.9% clones with sequence 
homology to HIV-1 (Fig. 2a, Supplementary Table 1), respectively. While the 
achieved enrichment for HIV-1 sncRNAs was already more than an order of 
magnitude higher than frequencies reported in the previously published studies, we 
aimed to further enrich HIV-1 sncRNAs by performing a second round of 
hybridization capture. We generated in total seven sncRNA libraries that underwent 
two consecutive hybridization selections and were all highly enriched for HIV-1 
sncRNAs yielding on average 78.3% (±7.6% (SD)) HIV-1 encoded clones (Fig. 2a, 
Supplementary Table 1). These results highlight that our approach has a striking 
capacity to enhance retrieval of low abundant sncRNAs. In our model system we 
achieved a greater than 100-fold increase in the selection of HIV-1 encoded sncRNA 
species over levels reported in the literature.  
 
For four libraries from two independent experiments (libraries F-J, Fig. 2a) we 
separated the dehybridized cDNA into two fractions of 50-80 and 80-110 base pairs 
length, which, after subtracting the lengths of adaptors and the C-tail, leads to 
lengths of HIV-1 sncRNAs of ≤25 and 25-55 bp, respectively, before subjecting the 
cDNA to a second round of hybridization enrichment. With this approach we wanted 
to explore if the target molecule length has an influence on hybridization efficacy. The 
latter was a reasonable concern as it was previously suggested that short molecules 
are difficult to select by hybridization capture19. However, we could not confirm this in 
our setup. While as expected the separate size selection resulted in a significant 
difference of the median size of sncRNAs (25 nt [interquartile range, IQR: 22-33] and 
44 nt [IQR: 33-51] for the 50-80 and 80-110 bp fraction, respectively, p<0.0001, 
Wilcoxon rank sum test) (Fig. 2b), the specificity of the hybridization capture for the 
smaller size sncRNA fraction was only slightly lower than for the larger size fraction 
(69.5% vs. 81.3% HIV-1 sncRNAs). 146 of 364 (40.1%) sncRNA clones showed a 
length of 20-25 nucleotides in the smaller size fraction as compared to 41 of 386 
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(11.1%) in the larger size fraction (p<0.0001, Chi square test). We can safely 
conclude that also sncRNA clones of smaller size can be efficiently derived using our 
hybridization capture.  
 
 
 
Figure 2. Efficiency of hybridization capture to enrich HIV-1 encoded sncRNAs. (a) 
Comparison of published data using the currents standard protocols (left) with our novel 
selection strategy (right). Standard protocols with no selection led to a yield of 0.1-0.5% HIV-
1 sncRNAs10,12 (and Schopman, N., Bradley, T., Willemse, M., van Kampen, A., Baas, F., 
Berkhout, B., Haasnoot, J., Keystone Symposia, Whistler, Canada, 20-25 March 2011, 
abstract #418). Numbers above bars indicate the respective literature references. Using our 
novel method, application of one round of hybridization capture yielded 8.9±5.7% (mean±SD) 
HIV-1 sncRNAs (libraries A and B). Performing two consecutive rounds of selection (libraries 
C-J) optimized the yield to 78.3±7.6% (mean±SD) HIV-1 sncRNAs. (b) Probing the influence 
of target molecule length on hybridization efficacy. Libraries F, G, H and J underwent a 
second size separation step before undergoing a second round of hybridization enrichment. 
Dehybridized cDNA was separated into two fractions of 80-110 bp or 50-80 bp length and 
both probed separately for hybridization efficacy. Green full circles denote HIV-1 derived 
sncRNAs, black open circles denote non HIV-1 sncRNAs. Both fractions successfully 
retrieved sncRNA in the second round hybridization. 20-25 nucleotide long sncRNAs were 
retrieved from both fractions and comprised 40.1% of all sncRNAs in the small size fraction 
and 11.1% in the large size fraction (p<0.0001, Chi square test). 
 
 
To verify that the individual HIV-1 ssDNA hybridization probes used select 
specifically HIV-1 sncRNAs of the respective region, we generated two libraries (H 
and J) where HIV-1 ssDNA hybridization probes were utilized in separate reactions in 
the two rounds of selection. We found that 92.8±7.9% (mean±SD) of the thereby 
recovered HIV-1 sncRNAs were specifically enriched (Supplementary Table 2). 
Interestingly, HIV-1 sncRNAs within the RU5 region (contig 2, Supplementary Table 
CHAPTER 2 
 63
3) could be selected with each HIV-1 ssDNA hybridization probe, regardless of the 
specific sequence. The latter possibly indicates a higher abundance within the HIV-1 
sncRNA species, or a sequence homology-independent binding modus to the HIV-1 
RNA genome. 
 
Characterization of HIV-1 small noncoding RNAs 
In total, we derived 1,335 clones from nine individual sncRNA libraries generated 
from HIV-1 infected primary cells after one or two rounds of hybridization capture (A-
J, Supplementary Table 1). Clones were defined as valid sncRNA candidates when 
they 1) contained the C-tail and the 3’ and 5’ adaptor sequences and 2) were in the 
expected size range (>15 and <100 nt). 892 of these clones had a greater than 90% 
homology to the strain HIV-1JR-FL used for infection. Of these, 216 clones were 
distinguishable as unique clones by various measures (e.g., derived from different 
libraries or differed in length and/or position; Supplementary Table 3). It can be 
reasoned that identical clones within one library may indicate sncRNA species which 
occur at higher abundance. However, deriving quantitative conclusions from our type 
of analysis is difficult as it cannot be ruled out that preferential amplification of certain 
clones occurred during PCR. 
 
We aligned the 216 unique HIV-1 sncRNAs to the reference strain HIV-1HXB2 (Fig. 3a, 
Supplementary Table 3). They had a length of 43±14 nucleotides (mean±SD, range: 
16-89 nt) (Fig. 3b). Based on this alignment we found that the derived HIV-1 
sncRNAs grouped within 67 different contigs, i.e., single or clusters of overlapping 
HIV-1 sncRNAs. 45 contigs (67.2%) contained 2 to 17 unique sncRNAs; 37 contigs 
harbored sncRNAs identified in at least two different libraries highlighting that these 
sncRNAs were not formed randomly. The contigs were spread throughout the HIV-1 
genome and the majority of them consisted entirely of sense sncRNAs (56 contigs, 
84%). 21 antisense sncRNAs were detected in either antisense only contigs (6 
contigs, 9%) or in mixed sense and antisense contigs (5 contigs, 7%). Of note, 
sncRNAs with differential polarity in these mixed contigs have the potential to form 
double-stranded sncRNAs.  
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Figure 3. Alignment and characterization of identified sncRNAs. (a) 216 unique sncRNAs 
from nine libraries (Supplementary Table 3) were aligned to the reference strain HIV-1HXB2 
and cluster in 67 contigs distributed throughout the whole genome of HIV-1. The coverage of 
sncRNA per nucleotide, the single unique clones (black: sense HIV-1 sncRNAs, pink: 
antisense HIV-1 sncRNAs), and the contig numbers are shown. (b) The length (nucleotides, 
nt) distribution of all unique HIV-1 sncRNAs is depicted. Sense sncRNAs are shown in black, 
antisense sncRNAs are shown in pink. (c) Pie chart depicting the distribution of different 
human cellular sncRNAs in all libraries. 
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Our selection procedure was highly successful in both, selecting a high number of 
HIV-1 sncRNAs but also in defining new HIV-1 sncRNA species. Of the identified 216 
unique HIV-1 sncRNAs, eight correspond to previously described HIV-1 miRNAs: Six 
sncRNAs correspond to hiv1-miR-N36717 within nef, one to hiv1-miR-TAR-3p15 and 
one to hiv1-miR-H118. Of particular note, while not identical in sequence and length, 
approximately 70% of our HIV-1 sncRNAs overlap with the 125 HIV-1 sncRNAs 
detected by pyrosequencing12. 
 
Although our selection strategy for HIV-1 encoded sncRNAs is highly effective, we 
still retrieved approximately 30% of sncRNAs which were not of HIV-1, but most of 
them of human origin. Other clones contained plasmid-derived, bacterial or unknown 
sequences, i.e., sequences without a match in the GenBank database. The majority 
of those human sequences (86%) could be assigned to various classes of human 
cellular sncRNAs, i.e., miRNAs, small nucleolar RNAs and transfer RNAs (Fig. 3c). 
As expected, tRNALys was frequently found since this tRNA functions as primer for 
the initiation of reverse transcription of the HIV-1 RNA.  
 
HIV-1 sncRNA contigs identify regions for sncRNA generation across different 
exemplary HIV-1 primary virus isolates  
While we were successful in demonstrating that sncRNAs are generated in HIV-1 
infected cells, our analysis was based on the virus isolate JR-FL. We thus sought to 
explore whether the identified sncRNAs are specific for this particular virus or are 
ubiquitously generated in HIV-1 infection. As proof-of-principle, we investigated the 
presence of three sncRNA contigs (contig 2, located in the conserved LTR region, 
and contigs 43 and 58 both located in env, Supplementary Table 3) in PBMC from 
HIV-1 uninfected donors infected with five unrelated patient-derived primary virus 
isolates, which were obtained during acute HIV-1 infection20. Isolates were chosen 
based on the patient-specific sequences of the env gene (Philip Rieder, Beda Joos, 
unpublished data) to assure annealing of the specific sncRNA primers. By specifically 
tailored RT-PCR all three HIV-1 sncRNA contigs were detected in most of the 
infected cultures (Fig. 4a), indicating that these sncRNAs are not specific for an 
individual virus strain, nor produced randomly as they emerge upon infection with 
genetically divergent HIV-1 strains.  
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Figure 4. Functional analysis of HIV-1 sncRNAs. (a) CD4+ T-lymphocytes of three healthy 
donors were infected with the indicated five different HIV-1 primary isolates and screened for 
the presence of HIV-1 sncRNAs in 3 contigs (contigs 2, 43 and 58) identified in HIV-1JR-FL 
infected cultures. Cell cultures from three HIV-1 negative donors were probed for each virus 
and the cultures which scored positive for the respective HIV-1 sncRNAs are depicted in red 
squares. (b) Predicted secondary structures of sncRNALTR6, hybrids of sense and antisense 
orientated clones from contig 58, namely sncRNAenv183, sncRNAenv184 and sncRNAenv185, 
and the positive control siRNA-M184 pol29 (Supplementary Table 3) are depicted. (c) Inhibition 
of HIV-1 replication in primary macrophages by HIV-1 sncRNAs. Macrophages were infected 
with HIV-1JR-FL seven days before transfection with sncRNAs. On day 0 cells were 
transfected with 50 nM of the indicated sncRNA (sncRNALTR6 (green), sncRNAenv183&185 
(orange), sncRNAenv184&185 (red)) and viral replication was monitored by p24 ELISA on 
days 0, 5, 9 and 13 post transfection. Mock transfected (black), scrambled sncRNA (blue) 
and siRNA nonsense (grey) were used as negative control, and siRNA-M184 pol29 (open 
circles) as positive control. 
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Specific HIV-1 sncRNAs can inhibit virus replication 
Considering the large number of HIV-1 sncRNAs we isolated and their variable 
length and orientation, it remains prudent to explore whether the various sncRNA 
species identified have functional properties or largely consist of degradation 
products which also may be generated in a sequence specific manner. Functional 
screening of all 67 HIV-1 specific contigs was beyond the scope of the current 
analysis. Here we focused in a proof-of-principle analysis on contigs 2 and 58. These 
contigs were chosen based on their secondary structures, which resembles 
precursor miRNA-like (contig 2) and siRNA-like features (contig 58). Of note, contig 
58 contains sense and antisense sncRNAs. We thus chose two individual 
sense/antisense pairs form this contig which may form hybrids and potentially act like 
siRNAs (Fig. 4b). To explore if these sncRNAs have any functional impact on HIV-1 
replication, primary macrophages infected with HIV-1JR-FL were transfected with HIV-
1 sncRNAs. While virus replication continued in mock, sncRNA and siRNA control 
cell cultures, HIV-1 production was potently inhibited both by the positive control 
siRNA-M184pol and the two contig 58 hybrids (Fig 4c). Both inhibited virus replication 
up to 90% compared to siRNA nonsense. How these RNA hybrids precisely function 
to downregulate HIV-1 production is currently under investigation. In contrast, the 
single-stranded, hairpin forming sncRNALTR6 had no effect on virus replication in 
primary macrophages in the probed setting (Fig. 4c). This preliminary analysis does 
not allow to define the latter as mere degradation product as we cannot rule out 
functional properties of this sncRNA, e.g., during earlier steps of virus replication. 
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Discussion 
 
Here we report on a novel, highly efficient selection method for sncRNAs of low 
abundance. The latter has proven technically very challenging which may lead to an 
underestimation or no evidence of low abundant sncRNAs. For a model, we have 
chosen HIV-1 encoded sncRNAs as they were only detected in very low frequencies 
of 0.1-0.5% in previous studies10,12 (and Schopman, N. et al., Keystone Symposia, 
abstract #418), if at all13. Our novel strategy relies on the introduction of a crucial 
selection step for sncRNAs homologous to HIV-1. We achieved this by adding a 
hybridization capture step into an improved cloning protocol for identifying sncRNAs. 
The hybridization capture was performed with HIV-1 ssDNA hybridization probes, 
covering the whole HIV-1 genome, that were attached to streptavidin beads. Applying 
two rounds of hybridization capture enabled us to enrich the frequencies of selected 
low abundant HIV-1 sncRNAs more than 100-fold over what has been reported10,12 
(and Schopman, N. et al., Keystone Symposia, abstract #418). Importantly, more 
than 70% of all obtained sncRNAs were of viral origin. This is a particular advantage 
of our strategy. While high-throughput sequencing techniques certainly have the 
capacity to overcome the limitations in identifying low abundant sncRNAs, it must still 
be considered that more than 99% of sequenced sncRNAs retrieved by random 
sequencing will not be of interest and very low abundant sncRNAs might still be 
missed. Our approach allows sequence specific selection with a high sensitivity. This 
is particularly highlighted by the fact that we succeeded in detecting antisense HIV-1 
sncRNAs despite the fact that HIV-1 antisense transcripts are described to be 
generated only at extremely low rates21-24. 
 
Separate sncRNA libraries derived from infected primary cells were generated, in 
which 216 unique HIV-1 sncRNAs with a mean length of 43 nucleotides were 
identified. Although, only 8% of the clones were of lengths described for genuine 
miRNAs or siRNAs, it has to be considered that longer HIV-1 sncRNAs still may have 
regulatory functions as recently reported25,26. Another possibility is that those longer 
HIV-1 sncRNAs represent precursor molecules of miRNAs. It has been postulated 
that short molecules are less likely to be selected by hybridization capture19. 
However, as we show here also sncRNAs of lower length can be efficiently enriched 
by extracting shorter RNA molecules during size selection steps. 
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Amongst all the different types of sncRNAs identified in our screen, the capture of 
antisense HIV-1 sncRNAs was most surprising to us. Whether or not antisense HIV-1 
RNAs are generated has been highly debated in the past and only few reports on 
HIV-1 antisense RNAs can be found in the literature21-24. It has been reasoned that 
the generation of antisense HIV-1 sncRNA might indeed be possible and occur via 
the HIV-1 promoter in the 3’LTR23 or via cellular promoters downstream of the 
integration site27. 
 
Many questions regarding the generation of viral sncRNAs during the HIV-1 life cycle 
and their function can and need to be addressed based on our initial observations 
and findings. Most importantly the high number of sncRNAs identified raises the 
possibility that also HIV-1 RNA degradation products were selected. Indeed this 
cannot be ruled out entirely and functional analysis of all sncRNAs is certainly 
warranted. However, it is important to note that our procedure excludes the selection 
of degradation products generated by the classical pathways of RNA degradation 
which generate fragments lacking the 3’- and 5’-end modifications necessary for C-
tailing and adaptor ligation28. 
 
Using the virus strain JR-FL we retrieved a vast number of HIV-1 sncRNAs. Of 
particular interest for us was to define whether these sncRNAs were specific for HIV-
1JR-FL only or were ubiquitously generated in HIV-1 infection. As proof-of-principle we 
investigated this for three contigs. Notably we found that sncRNAs of all three contigs 
were generated in cells infected with unrelated HIV-1 primary virus isolates, thus, 
confirming that the generation of these RNA species is not virus strain dependent.  
 
Many potential functional properties of HIV-1 specific sncRNAs can be envisioned 
with both infection enhancing or reducing capacity. Here we report on functional 
assessment of sncRNA candidates from two of the 67 identified contigs. The 
hybridizing sense and antisense HIV-1 sncRNAs of contig 58 displayed a siRNA-like 
HIV-1 inhibition pattern in primary macrophages. As we demonstrate here, antisense 
sncRNAs appear to be generated during HIV-1 infection and thus might have the 
potential to downregulate HIV-1 production. This obviously raises a number of 
questions: Why would HIV-1 give raise to such negative regulatory RNAs? If they act 
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in vivo, would HIV-1 not rapidly escape and induce countermeasures? Or are these 
negative regulators necessary for a balanced virus production (e.g., ascertaining 
appropriate generation of structural proteins) or maybe in inducing latency? Now that 
our novel sncRNA isolation procedure provides the means to enrich and select these 
types of HIV-1 sncRNAs with high efficacy these functional analysis become for the 
first time feasible.  
 
In summary, using hybridization capture for detection of novel sncRNAs of low 
abundance is a highly sensitive approach. This is particularly highlighted by the 
efficient enrichment of low abundant sncRNAs. More than 70% of sncRNAs we 
identified in our HIV-1 targeted screen were indeed derived from HIV-1 RNA 
demonstrating a high specificity of this enrichment by hybridization capture. The 
procedure proved highly reproducible and robust, as indicated by similar efficacy of 
sncRNA selection in all independent libraries and the identification of similar types of 
sncRNAs in independent experiments, respectively. Our targeted enrichment method 
to detect sncRNAs of low abundance by hybridization capture is highly efficient and 
the method would thus lend itself towards application in similar biological settings 
where low abundant sncRNAs need to be identified. 
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Methods 
 
Viruses 
Primary HIV-1 isolates20 were derived from patients' peripheral blood mononuclear 
cells (PBMC) by co-culturing patient CD4+ T-lymphocytes with stimulated, CD8-
depleted PBMC as previously described30. Patients were enrolled in the Zurich 
primary HIV infection (ZPHI) study (http://clinicaltrials.gov: NCT00537966) and 
written informed consent was obtained from all participants. Viral replication was 
assessed from culture supernatants by p24 ELISA (adapted from31). TCID50 of 
primary isolates and PBMC grown HIV-1JR-FL virus stocks was estimated as 
described32.  
 
Cells and infection 
PBMC from three healthy donors were isolated, CD8+ T-cell depleted and cultured as 
described previously32. For stimulation of CD4+ T-lymphocytes, cells were divided in 
3 parts and cultured in the presence 0.5 μg/ml phytohemagglutinin (PHA), 5 μg/ml 
PHA, or anti-CD3 antibody OKT3 hybridoma supernatant32. After 72 h, cells from all 3 
stimulations were combined. Cells were infected with HIV-1JR-FL (MOI = 0.01), 
harvested 7 days post infection and lyzed using QIAzol lysis reagent (Qiagen). Virus 
replication was monitored by p24 ELISA. 
 
For the generation of macrophages, primary human monocytes were isolated from 
CD8+ T-cell depleted PBMC using positive selection with anti-CD14-coated magnetic 
beads (Miltenyi Biotech). Monocytes (3x106 cells per T25 flask) matured to 
macrophages in the presence of 0.02 μg/ml human M-CSF (macrophage colony 
stimulating factor, PeproTech). Macrophages were maintained in RPMI-1640 
supplemented with 10% FCS, 1% penicillin/streptomycin, 5% MCM (macrophage 
conditioned medium, sterile-filtered), 5% human serum and 0.02 μg/ml M-CSF (the 
latter three ingredients were added only during the first 6-8 days). After 14 days of 
maturation, macrophages were infected with HIV-1JR-FL (MOI = 0.01). Medium was 
changed 16 h post infection and virus replication was monitored by p24 ELISA. After 
another 14 days, cells were harvested and lyzed using QIAzol lysis reagent (Qiagen). 
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Isolation of the low molecular weight RNA fraction 
Lyzed cells were homogenized with QIAshredder (Qiagen) and the extraction of 
small RNA (<200 nt) was performed using miRNeasy Mini Kit (Qiagen). Briefly, the 
flow through after homogenization was supplemented with 140 μl chloroform, 
thoroughly mixed and centrifuged for 15 min at 13,500 g. The upper phase containing 
the RNA was supplemented with 1 volume ethanol (70%) and transferred to a spin 
column. After centrifugation for 15 s at 8,000 g, the column containing RNA 
fragments >200 nt was discarded, while the flow through with the small RNA 
fragments (<200 nt) was saved. 450 μl of ethanol (100%) were added to the flow 
through, mixed thoroughly and transferred to an RNeasy MinElute spin column 
(Qiagen). After centrifugation for 15 s at 8,000 g, the column was washed with buffer 
RPE and 80% ethanol according to the manufacturers’ instructions. RNA was eluted 
in 40 μl RNase-free water. The RNA was quantified with Nanodrop 1000 (Thermo 
Scientific).  
 
Adaptor addition and cDNA synthesis 
An aliquot (15 μl) of the low molecular weight fraction of extracted RNA was C-tailed 
for 15 min at 37°C using 7.5 units E.coli Poly(A) Polymerase (New England Biolabs) 
and 0.75 mM CTP (Connectorate). The synthesis of C-tails was blocked by addition 
of 0.5 mM Cordycepin (5’-triphoshpate sodium salt, Sigma-Aldrich) and 2.5 units 
E.coli Poly(A) Polymerase, and incubation for 15 min at 37°C. At the same time, C-
tailed RNA was treated with 15 U DNase (DNase I recombinant, RNase-free; Roche). 
Afterwards, precipitation was performed by adding 1 volume isopropanol, 0.2 M 
sodium acetate and 4 µl precipitation carrier Dr. Gentle (Takara) and centrifuged for 
30 min at 16°C and 16,000 g. The pellet was washed with 80% ethanol and eluted in 
20 μl H2O. Subsequently, the 5’-end was ligated to an 2’ O-methylated RNA adaptor 
5’-AUCGGAACAUCCAGACAUAACA-3’ using 40 U T4 RNA ligase (New England 
Biolabs), 4 μM adaptor RNA and 60 U RNaseOut (Intvitrogen) (15 min at 37°C and 
over night at 16°C). This was followed by precipitation as described above and 
elution in 10 µl H2O. cDNA was generated using M-MuLV Reverse Transcriptase 
(Finnzymes) and the 3’ linker primer mf331 5’-
ACCAGAGTGCGAGTAGGAAGATTGGGGGGGGG-3’ partly complementary to the 
C-tail of the RNA in a final volume of 20 µl. Briefly, RNA and 5 μM primer were 
denaturated for 5 min at 95°C followed by incubation on ice for at least 2 min. The 
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enzyme-buffer-dNTP (400 U M-MuLV Reverse Transcriptase, 2.5 mM dNTP) mixture 
was added and the reaction was incubated for 60 min at 37°C. Amplification of 2 µl 
cDNA was executed with JumpStart Taq ReadyMix (Sigma-Aldrich) for 15 cycles 
using 1 μM 5’ adaptor primer mf311 5’-ATCGGAACATCCAGACATAACA-3’ and 1.5 
mM MgCl2 in a final volume of 50 μl (95°C-5'; 15x (95°C-5''; 52°C-5''; 72°C-40'')). 
 
A second round of PCR with 25 cycles was performed using 1 µl of a 1:10 dilution of 
the first PCR product. Again JumpStart Taq ReadyMix (Sigma-Aldrich) supplemented 
with 1.5 mM MgCl2 and 1 μM of each 5’ and 3’ adaptor primers mf311 and mf315 5’-
ACCAGAGTGCGAGTAGGAAGATT-3’ was used in a final volume of 30 μl (95°C-2'; 
25x (95°C-5''; 52°C-5''; 72°C-20'')). Amplicons were precipitated with isopropanol and 
dissolved in TENT5/200 (10 mM Tris-HCl, 5 mM EDTA, 0.2 M NaCl, 0.1% Triton) in a 
final volume of 40 μl. All RNA and DNA oligonucleotides were synthesized by 
Microsynth. 
 
Generation of HIV-1 DNA/Streptavidin beads for selection of HIV-1 sncRNAs 
The HIV-1JR-FL plasmid33 was used as template and amplified with HIV-1 specific 
biotinylated primers, using the HotStartTaq Master Mix Kit (Qiagen) supplemented 
with 1.5 mM MgCl2 in a final volume of 50 μl (95°C 15'; 40x ( 95°C 10'' - 57°C 10'' - 
72°C 4'); 72°C 7'). Five amplicons were generated using the following primers that 
are biotinylated at the 5’-end: 1) TAR to gag (position according to HIV-1HXB2 
(GenBank accession number K03455): 455-1,658) with the primers mf271 5’-
GGTCTCTCTGGTTAGACCAGATTTGA-3’ and sk39 5’-
TTTGGTCCTTGTCTTATGTCCAGAATGC-3’, 2) gag to pol (1,273-4,837) with mf219 
5’-AAGGCTTTCAGCCCAGAAGTAATACCCATGTT-3’ and mf255 5’-
ATGTCTACTATTCTTTCCCCTGCA-3’, 3) pol to env (4,758-6,741) with mf254 5’-
CAAATGGCAGTATTCATCCACAA-3’ and mf237 5’-
ATTCTTCCTGATCCCCTTCACTCTCAT-3’, 4) env (5,956-8,421) with mf1 5’-
CTTAGGCATCTCCTATGGCAGGAA-3’ and mf2 5’-
TTCCTTCGGGCCTGTCGGGTCCC-3’ and 5) splice acceptor 7 (sA7) to the 3’LTR 
(8,317-9,700) with mf214 5’-TTTTTGCTGTACTTTCTATAGTGAATAGAGTTA-3’ and 
cr2 5’-TGACTAAAAGGGTCTGAGGGATCTCTAGTTACCAG-3’. All primers were 
used in a final concentration of 1 μM. The PCR products were purified (Qiaquick, 
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Qiagen) and eluted in 10 mM Tris-HCl (pH 8.5). All primers were synthesized by 
Microsynth. 
 
Biotinylated DNA was attached to streptavidin beads (Roche). Either 400 ng of 
biotinylated DNA from each PCR was used separately, or in combination (5 x 400 ng) 
for preparation of the beads. Briefly, 25 µg beads were washed with TENT100 buffer 
(10 mM Tris-HCl, 1 mM EDTA, 100 mM NaCl, pH 7.5, 0.1% Triton) and resuspended 
in 75 µl 2xTENT100. Denaturated amplicons (5', 95°C) were added to the beads and 
the volume was adjusted to 150 µl with H2O. DNA was immobilized by 30 min 
incubation with the beads at 37°C. Streptavidin-biotinylated, single-stranded DNA 
complexes were achieved by heating to 90°C for 1 min. The attachement-
dehybridization procedure was repeated once. Streptavidin-biotinylated-ssDNA 
complexes were washed 3 times with TENT1000 (10 mM Tris-HCl, 1 mM EDTA, 1 M 
NaCl, pH 7.5, 0.1% Triton) and 3 times with TENT100. They were stored in TENT100 at 
4°C.  
 
Selection of HIV-1 sncRNAs 
For the hybridization of amplified HIV-1 sncRNAs to the Streptavidin-biotinylated-
ssDNA complexes, 10 µl of these beads were added to the amplified HIV-1 sncRNAs 
and incubated for 3 min at 95°C followed by a cool down to 50°C over night on a 
head to tail wheel. Beads were washed 4 times with pre-warmed (50°C) TENT5/200 
buffer. Annealed amplified HIV-1 sncRNAs were eluted from the beads by adding 15 
µl Tris-HCl buffer (10 mM Tris-HCl, pH 8.5) and heating for 5 min at 95°C. Beads and 
eluted sncRNA were separated by magnetic separation. HIV-1 sncRNAs were 
amplified using JumpStart Taq ReadyMix (Sigma) supplemented with 1.5 mM MgCl2 
and 1 uM of each adaptor-specific primers mf311 and mf315 (95°C-2'; 30x (95°C-5''; 
52°C-5''; 72°C-30'')) in a final volume of 30 μl. Amplicons were size-separated using 
a 3% MetaPhor agarose gel. DNA with a length of 50-110 bp was extracted from gel 
using GenElute Agarose Spin Columns (Sigma) according to the manufacturer’s 
instruction. When two selection steps were performed, eluate was precipitated with 
isopropanol and the hybridization and size selection steps were repeated. Eluates 
were precipitated with isopropanol and eluted in 15 ul H2O. 
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Cloning and Sequencing of HIV-1 sncRNAs 
Amplified and selected HIV-1 sncRNAs were ligated into the vector pDrive using the 
QIAGEN PCR Cloning kit (Qiagen) according to manufacturer’s instruction. Single 
clones were sequenced in one direction with the primer T7 using BigDye chain 
terminator chemistry and the automated sequencer ABI 3100 (Applied Biosystems). 
Sequences were controlled for the presence of both adaptor sequences, which were 
subsequently deleted to obtain the sncRNA sequence. This analysis was performed 
using the software BioEdit34. All sncRNA sequences were aligned to the reference 
strains HIV-1HXB2 and HIV-1JR-FL using the software DNAstar (DNA-star Madison). 
Sequences with >90% homology to the reference strain HIV-1JR-FL were considered 
HIV-1 specific. FASTA35 was chosen for further nucleotide similarity searches. 
Classification of small RNA sequences was based on sequence analysis using the 
GenBank database (http://www.ncbi.nlm.nih.gov/genbank/), the miRNA registry 
database (http://www.mirbase.org/) and the human tRNA database 
(http://gtrnadb.ucsc.edu/). Secondary structures of selected HIV-1 sncRNA were 
predicted with RNAstructure 5.236. SncRNA sequences smaller than 16 nucleotides 
were not included in our analysis.  
 
Statistical analyses 
Statistical analyses were performed using GraphPad Prism5.0 software. The two-
tailed Chi square test and the Wilcoxon rank sum test were used for binary and 
cardinal data, respectively. p<0.05 was considered statistically significant. 
 
Transfection of primary macrophages with HIV-1 sncRNAs 
Maturated macrophages were generated and infected with HIV-1JR-FL as described 
above. Seven days after infection cells were transfected with HIV-1 sncRNAs using 
jetPRIME transfection reagent (Polyplus-Transfection). Briefly, medium was replaced 
by Opti-MEM® I Reduced Serum Media (Invitrogen) and the transfection mix was 
added to the cells according to the manufacturer’s instructions. After four hours, 10 % 
FCS (Invitrogen) was added. The next day the transfection medium was replaced by 
RPMI-1640 supplemented with 10% FCS and 1% penicillin/streptomycin.. Virus 
replication was observed by p24 ELISA. Following oligonucleotides were used for 
sncRNA transfection: sncRNALTR6; sncRNAenv183; sncRNAenv184; sncRNAenv185 
(Supplementary Table 3). Control siRNA labelled with AlexaFluor488 (AllStars 
CHAPTER 2 
 84
negative controls, Qiagen), here named as siRNA nonsense, was used as control for 
the transfection efficiency and negative control for virus inhibition, whereas siRNA-
M184pol was chosen as positive control as previously described29. 
 
Detection of HIV-1 sncRNAs in cells infected with primary HIV-1 isolates  
HIV-1 sncRNAs detected in most or all of the libraries, were screened in terms of 
their presence in primary cells infected with primary HIV-1 isolates. Infection of CD8-
depleted PBMC, RNA isolation, C-tailing and reverse transcription was performed as 
described above. HIV-1 sncRNAs were amplified. Briefly, PCR reactions contained 
1x PCR buffer (Sigma), 0.67x Eva-Green (Brunschwig), 3 mM MgCl2, 0.2 mM 
dNTPs, 1 uM of primer mf315, 1 uM of respective HIV-1 sncRNA-specific primer 
(mf382 5’- ATAAAGCTTGCCTTGAGTG-3’, mf178 5’- 
ATGGTAGAACAGATGCATGAGGATATAAT-3’, CA-179 5’- 
CGTTCACTAATCGTCCGGATCTGTC-3’) and 0.03 U/μl JumpStart Taq DNA 
Polymerase (Sigma). PCR was performed as follows: 95°C-2'; 50x (94°C-10''; 55°C-
10''; 72°C-40''). Amplicons were loaded on 3% MetaPhor agarose gel and separated 
by electrophoresis mobility. 
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Own contributions 
 
Benefits of early treatment in acutely HIV-1 infected patients remain controversial. 
Despite considerable side effects and also costs, which need to be taken into 
account in relation to decades of expected treatment time, early treatment may 
prevent expansion of the latent reservoir as well as viral escape to HIV-1 specific 
immune responses as viral diversity remains low. Thus, in this study, intra- and 
extracellular viral dynamics were assessed before, during, and after treatment of 
acute HIV-1 infection. For this purpose, HIV-1 RNA transcription patterns in PBMC 
and levels of plasma viremia were monitored. Comparison with a group of patients, 
who had initiated combination antiretroviral therapy (cART) during chronic infection, 
was performed cross-sectionally. 
My contributions to this study were based on the quantitative PCR (qPCR) assays 
described in chapter 2 (Althaus et al., 2010). Measuring HIV-1 RNA transcription 
patterns in PBMC isolates of HIV-1 infected patients requires single copy sensitive 
qPCR, especially in patients under cART. Therefore, different primer and FH-probe 
combinations published in the previous paper were used in this study. Additionally, 
because of the high variability of the HIV-1 genome, I assisted in the search for 
optimal patient matched, i.e., sequence-adapted primers and FH-probes by applying 
the established rules regarding both target conservation and physical properties, 
such as melting temperatures, baseline fluorescence and secondary structure. 
Furthermore, I supervised the qPCR procedures, and helped in analyzing and 
interpreting the qPCR data. 
Single copy sensitive assays were essential for this study as one major finding was 
that unspliced RNA was detectable during cART in 42% of patients with cART 
initiated during acute HIV-1 infection as opposed to 87% of patients, who initiated 
cART during chronic HIV-1 infection; a statement that could not have been made 
without highly sensitive assays. This work indicates that early intervention results in 
profound depletion of PBMC expressing HIV-1 RNA, which is contrary to chronically 
infected patients on cART. 
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Profound Depletion of HIV-1 Transcription in Patients 
Initiating Antiretroviral Therapy during Acute Infection 
 
Adrian Schmid*, Sara Gianella*, Viktor von Wyl, Karin J. Metzner, Alexandra U. 
Scherrer, Barbara Niederöst, Claudia F. Althaus, Philip Rieder, Christina Grube, 
Beda Joos, Rainer Weber, Marek Fischer, Huldrych F. Günthard 
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*These authors contributed equally to the manuscript. 
 
Background: Although combination antiretroviral therapy (cART) initiated in 
the acute phase of HIV-1 infection may prevent expansion of the latent 
reservoir, its benefits remain controversial. In the current study, HIV-1 RNA 
transcription patterns in peripheral blood mononuclear cells (PBMC) were 
monitored during acute cART to assess the effect of early treatment on cellular 
viral reservoirs. 
Methodology/Principal Findings: Acutely HIV-1 infected patients (n=24) were 
treated within 3-15 weeks after infection. Patients elected to cease treatment 
after ≥1 year of therapy. HIV-1 DNA (vDNA), HIV-1 RNA species expressed both 
in latently and productively infected cells, unspliced (UsRNA), multiply spliced 
(MsRNA-tatrev; MsRNA-nef), and PBMC-associated extracellular virion RNA 
(vRex), expressed specifically by productively infected cells, were quantified in 
PBMC by patient matched real-time PCR prior, during and post cART. In a 
matched control-group of patients on successful cART started during chronic 
infection (n=15), UsRNA in PBMC and vDNA were measured cross-sectionally. 
In contrast to previous reports, PBMC-associated HIV-1 RNAs declined to 
predominantly undetectable levels on cART. After cART cessation, UsRNA, 
vRex, and MsRNA-tatrev rebounded to levels not significantly different to those 
at baseline (p>0.1). In contrast, MsRNA-nef remained significantly lower as 
compared to pretreatment (p=0.015). UsRNA expressed at the highest levels of 
all viral RNAs, was detectable on cART in 42% of patients with cART initiated 
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during acute infection as opposed to 87% of patients on cART initiated during 
chronic infection (Fisher’s exact test; p=0.008). Accordingly, UsRNA levels 
were 105–fold lower in the acute as compared to the chronic group. 
Conclusion: Early intervention resulted in profound depletion of PBMC 
expressing HIV-1 RNA. This is contrary to chronically infected patients who 
predominantly showed continuous UsRNA expression on cART. Thus, 
antiretroviral treatment initiated during the acute phase of infection prevented 
establishment or expansion of long-lived transcriptionally active viral cellular 
reservoirs in peripheral blood. 
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Introduction 
Current combination antiretroviral therapy (cART), despite its potency in suppressing 
active viral replication 1,2 and its power in reducing mortality and morbidity of HIV-1 
infection 3,4, has not resulted in eradication or induction of treatment-free periods of 
remission of HIV-1 replication 5-7. A pool of HIV-1 infected long-lived latently infected 
memory T-lymphocytes has been reported to be the major reservoir that confers HIV-
1 infection resilient to eradication 8-10. The frequency of latently infected cells was 
reported to range from 1 to 20 cells per 106 resting CD4+ T-cells 9. However, as these 
assays rely on technically demanding ex-vivo outgrowth assays, their results likely 
underestimate the size of the latent reservoir. Recent studies used PCR-based 
methods, in which latency had been defined as active viral transcription in the 
absence of viral progeny production. The resulting estimates of the size of the 
peripheral blood latent reservoir were at least 5-10 times higher in resting CD4+ T-
cells 11 as well as in total PBMC 12 when compared to viral outgrowth assays 9. Apart 
from cells in peripheral blood, other sites such as lymphoid tissues 13-15, the 
gastrointestinal tract 16-19, the brain 20, and the genital tract 21, have been reported to 
contribute to latent viral sanctuaries. 
Due to the low expression levels of viral RNA in latently infected cells 12,14,22-24 and 
viral antigens, the latent viral reservoir is greatly inaccessible for adaptive and innate 
immune defenses. It has been proposed that local bursts of viral replication are 
initiated by immune activation in response to specific antigens 25-27 or due to random 
self-activation by the viral transactivator Tat 28. In the presence of potent cART, such 
bursts will be dead-ended, because the viral particles produced may not initiate new 
rounds of infection. Conversely, after cessation of cART, this process will lead to 
rapid viral rebound 29 initiated stochastically from single or oligoclonal archival 
proviruses 30. 
Nevertheless, the canon that HIV-1 replication, as measured by levels of plasma 
viremia, will inevitably proceed in the absence of cART 31,32 or recur soon after its 
cessation 29,33 has been challenged by important exceptions. Due to strong and 
specific immunological responses, so called elite-controllers contain viral replication 
to levels below a clinically relevant threshold (<50 copies/ml) in the absence of cART 
(reviewed in 34). Furthermore, in some instances treatment initiated during the acute 
or early phases of HIV-1 infection had resulted in control of viremia after treatment 
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cessation 35-38. These anecdotal cases have been used as precedents supporting 
early treatment. In addition, two rationales have been proposed to affirm possible 
benefits of early treatment of HIV-1, despite considerable side effects 39-41 as well as 
costs 42,43, which need to be considered in relation to decades of expected treatment 
time. 
Paul Ehrlich’s paradigm to “hit early and hard” in treatment of infectious disease 44 to 
limit spread of an infectious pathogen and to contain its population size, toxicity, and 
its potential to escape immunological and chemotherapeutic/medical control 45 is still 
valid and accepted. This concept was substantiated for HIV-1 by Strain et al., who 
showed that the size of latent reservoirs was smaller in patients with treatment 
initiation in the acute phase than in those who initiated cART during chronic infection 
46. In addition to that, the notion that acute HIV-1 infection is generally associated 
with oligoclonal viral quasispecies of low phylogenetic diversity 47,48 led to the 
hypothesis that by early treatment viral escape to specific HIV-1 antibody- and 
cytotoxic T-cell responses may be avoided or deferred resulting in clinical benefit 
and/or virological control of the virus. This concept was corroborated by a study 
showing that transmission of multiple quasispecies was associated with faster 
disease progression than mono- or oligoclonal primary infection 49. Low viral diversity 
has also been shown to be associated with modest but significant control of viremia 
in chronic infection 50. Moreover, superinfection can lead to the loss of control of 
viremia 51-56.  
To elucidate these issues in the current study, intra- and extracellular viral dynamics 
were assessed before, during, and after treatment of acute HIV-1 infection. For this 
purpose HIV-1 RNA transcription patterns in PBMC and levels of plasma viremia 
were monitored. Comparison with a group of patients, who had initiated cART during 
chronic infection, was performed cross-sectionally. Unexpectedly, cell-associated 
viral RNA burden in PBMC became mostly undetectable in the acutely infected 
patient group. The levels of UsRNA, the most abundant cellular HIV-1 RNA in vivo, 
were at least one order of magnitude lower during cART initiated in acute than in 
chronic infection. These results strongly indicate that patients initiating cART in the 
acute phase of infection may attain a substantial virological benefit from early 
intervention. 
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Results 
Kinetics of viral RNA levels in response to treatment and cessation of cART 
Acutely HIV-1 infected patients (n=24) were treated with cART within 3-15 weeks 
after infection. Plasma viremia was monitored using standard diagnostic quantitative 
PCR-assays (qPCR) and PBMC-associated HIV-1 nucleic acids (figure 1) were 
quantified by patient matched qPCR 11,12,57,58. HIV-1 DNA (vDNA) was assessed as a 
measure of total infected cells, comprising latently and productively infected cells as 
well as cells harboring defective genomes. 
To investigate the activity of these HIV-1 infected cells, distinct PBMC-associated 
viral RNA species (vRNAs) were quantified: unspliced RNA (UsRNA) and 2 types of 
multiply spliced encoding tat and rev (MsRNA-tatrev) or nef (MsRNA-nef). These 
RNAs were found to be expressed both in latently 12,23,59 and productively infected 
cells, however, at much higher levels in the latter cell population. As a marker for 
productively infected cells, PBMC-associated extracellular virion RNA (vRex) was 
measured 11,12,14,22,57. 
Initiation of cART resulted in a decay of viral RNA production (figure 2 A/B left panel). 
Whereas plasma viremia followed kinetics which were consistent with a 2-3 phasic 
exponential decay, vRex dropped to undetectable levels almost instantly after 
initiation of cART. Decay of UsRNA and MsRNAs was intermediate between that of 
plasma viremia and vRex (data not shown). Upon cessation of cART, rebound of 
HIV-1 nucleic acids occurred quickly in plasma (figure 2A, right panel), but was 
apparently delayed in PBMC (figure 2B, right panel, figure 3B). 
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Figure 1: Map of HIV-1 amplica for qPCR assays. Splice acceptors and donor sites are 
shown by red and blue vertical lines, respectively. Exons are depicted in grey bars. Blue 
dotted lines show documented or predicted splice events. Sense primers used in qPCR 
assays are depicted by red arrows antisense/cDNA primers by blue arrows. Fluorescent 
hydrolysis probes 58 (FH-probes / TaqMan®-probes) are shown by green/pink bars. Assays 
for MsRNAs share a common antisense/cDNA primer and in some instances, when a probe 
for MsRNA-tatrev was not available, a common FH-probe 3’ of the splice-acceptor of the 2nd 
major intron. Note that this map does not show mRNAs encoding Env because these 
transcripts were not assessed in the current study. 
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Figure 2: Longitudinal course of HIV-1 virion production. Levels of plasma viremia (A) 
and of PBMC-associated virions, vRex (B) of 24 acutely infected patients, were plotted 
against time after initiation of cART (0 weeks, left panels) or against time after cART 
cessation (defined as 0 weeks in the right panels). Note that some data points are depicted 
in the left panels are also shown in the right panels to facilitate visualization of the effects of 
cART cessation. The amount of vRex measurements is lower, because cell sampling was 
done less frequently than plasma HIV-RNA was measured. Data within the grey horizontal 
areas show PCR-negative samples below the detection limit of the assays applied. The black 
line in panel A depicts the clinically used threshold for plasma viremia of 50 RNA copies/ml. 
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Time to event analysis of HIV-1 RNA detection during and after cART 
To corroborate these observations and to extend them to UsRNA and MsRNAs, 
empirical distributions of the proportions of patients with detectable viral RNAs after 
initiation of cART were plotted (figure 3A). Similarly, distribution of the proportion of 
patients experiencing viral rebound after therapy cessation was addressed (figure 
3B). Upon initiation of cART, disappearance of vRex took a median time of 4.5 weeks 
(quartiles 4, 6 weeks). Taking into account that the second sample following baseline 
in the current study was obtained at a median time of 4.4 weeks (quartiles 4, 5 
weeks) depletion of vRex occurred instantaneously after cART initiation. MsRNAs 
declined significantly later to undetectable levels (Mann-Whitney, p=0.002), namely 
within a median time of 8.4 weeks (quartiles 5, 13 weeks). The next parameter to 
reach its detection limit with a significant delay compared to MsRNA (Mann-Whitney, 
p=0.003) was UsRNA with a median time to the first undetectable measurement of 
13.5 weeks (quartiles 9, 47 weeks). Finally, plasma viremia dropped to undetectable 
levels within a median time of 24.6 weeks (quartiles 12, 44 weeks), which was not 
significantly different to the decay of UsRNA (Mann-Whitney, p=0.52). In general, 
after detection of the first undetectable HIV RNA value, all RNA species measured 
remained undetectable at almost all timepoints measured during treatment. 
After cessation of cART, plasma viremia reached levels above the threshold of 50 
copies/ml in a median time of 4.2 weeks (quartiles 3, 10 weeks). Rebound of UsRNA 
and MsRNA proceeded with some delay without reaching statistical difference 
(Mann-Whitney, p=0.30 and p=0.07, respectively): Median time to rebound was 8.0 
weeks (quartiles 4, 12 weeks) and 9.8 weeks (quartiles 4, 19 weeks) for UsRNA and 
MsRNA, respectively. Lastly, within a median time of 17.9 weeks (quartiles 8, 56 
weeks) vRex rose to detectable levels. Its rebound was statistically different from that 
of plasma viremia and of UsRNA (Mann-Whitney, p=0.007 and 0.02, respectively) but 
not from MsRNA (Mann-Whitney, p=0.06). It has to be noted that vRex was 
measured less frequently than plasma or PBMC viremia. Therefore the median time 
to rebound may have been overestimated. 
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Figure 3: Empirical distribution of times to virological end-points. Time to event 
analysis showing the percentage of patients before reaching their first PCR-negative 
measurement after initiation of cART (A) or reaching measurable viral RNA levels above a 
defined threshold after cessation of cART (B). Thresholds are indicated in parentheses in 
panel B and were defined as approximately 3-fold elevation over mean on cART levels for 
cellular HIV-1 RNAs. Threshold of plasma viremia was set at 50 copies/ml. On average vRex 
(red lines), MsRNAs (magenta), UsRNA (blue) and plasma viremia (red broken lines) 
dropped to undetectable levels 4.5, 8.4, 13.5, and 24.6 weeks after initiation of cART, 
respectively (A) and rebounded within 17.9, 9.8, 8.0, and 4.2 weeks after treatment cessation 
(B), (dotted lines). Note that for analysis of plasma viremia only time-points were considered 
for which also UsRNA and MsRNA measurements had been available. 
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Magnitude of viral nucleic acid levels at baseline and post-cessation 
To investigate whether cART initiated in acute infection had an impact beyond its 
cessation, the levels of HIV-1 nucleic acids at baseline and after treatment cessation 
were compared. Maxima were used to represent post-cessation HIV-1 nucleic acid 
levels, to account for the variability among the different parameters regarding the 
time to reach stable set-points. 
Plasma viremia (figure 4A) was significantly reduced after treatment cessation as 
compared to baseline (Wilcoxon signed rank test, p=0.002). This reduction can be 
attributed in part to the early treatment effect of cART (Gianella, von Wyl et al., 
unpublished data), but also to a naturally occurring “first peak” of viremia observed in 
acute HIV-1 infection 60. We observed a less pronounced impact of early cART on 
cellular viral nucleic acid levels after treatment cessation. Only MsRNA-nef showed 
persistent significant reduction after cART (Wilcoxon signed rank test, p=0.02), 
whereas the remaining parameters, vDNA, vRex, UsRNA, and MsRNA-tatrev (figure 
4B-E) tended to be lower after treatment stop compared to baseline but without 
reaching statistical significance (Wilcoxon signed rank test, p>0.10). 
 
 
Viral reservoirs during cART 
As opposed to baseline and post-cessation viral nucleic acid levels, which were 
represented by single measurements, on-cART levels were estimated by calculating 
means. Taking into account the rapid decay of vRex, the mean of samples at time-
points ≥2 weeks after initiation of treatment was used. For all other parameters 
measurements taken at time points ≥24 weeks were used for calculation of mean 
values. The rationale for choosing this time-window was that the parameter with the 
slowest decay kinetics, plasma viremia, reached undetectable levels within a median 
time of around 24 weeks as shown in figure 3A. Accordingly, the resulting mean 
values for plasma viremia on cART were well below the clinically used threshold of 
50 copies/ml (figure 4A), except for one patient (#133; 59 copies/ml). 
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Figure 4: Virological parameters before, during, and after cART. Viral nucleic acid levels 
at baseline (diamonds), and average values during the time windows defined as on cART 
(circles, vRex ≥2 weeks, plasma viremia, PBMC-associated UsRNA and MsRNAs ≥24 
weeks) and post-cessation maximal values (triangles). Data-points within the grey horizontal 
areas show PCR-negative samples below the detection limit of the assays applied. P-values 
within panels show significance levels (Wilcoxon signed rank test) between baseline and 
post-cessation. Bars show medians and quartiles. The dotted line in panel A depicts the 
clinically used threshold for plasma viremia of 50 RNA copies/ml. 
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HIV-1 DNA persisted at a level of 823±253 copies/106 PBMC (mean±sem) during 
cART initiated in acute infection. However, proviruses in these infected cells were 
transcriptionally almost completely silent. Expression of MsRNAs and vRex was 
mostly undetectable and attenuated to mean levels <1 copy/106 PBMC (MsRNA-
tatrev: 0.34±0.24, MsRNA-nef: 0.65±0.30, vRex: 0.29±0.19; mean±sem). Only 
expression of UsRNA was occasionally detected at a mean level of 2.6±1.2 
copies/106 PBMC. The absence of vRex during cART observed in the current study 
was similar to findings of previous studies 11,12,14,22 indicating a fast and complete loss 
of productively infected cells as a consequence of cART. However, the almost 
complete depletion of MsRNA and the profound reduction of UsRNA were highly 
unexpected, as we and others have shown their presence at measurable levels in 
latently infected cells of HIV-1 infected patients on cART 11,12,59. 
 
Comparison of the effects of cART initiated in primary versus chronic infection 
To investigate whether the observed depletion of viral transcription could be 
attributed to the early initiation of cART, PBMC obtained from patients, who had 
initiated antiretroviral therapy in the chronic phase of HIV-1 infection, were assessed 
for the presence of viral RNA in PBMC. Latently infected cells expressing solely 
UsRNA had been shown to persist during cART at the highest frequency among all 
cell classes expressing viral RNA and UsRNA had been consistently detected at the 
highest levels during cART in previous studies 11,12,57,61. Therefore, UsRNA and 
vDNA were quantified in patients in whom cART had been initiated during chronic 
infection (n=15, for patient characteristics see Table S1) using identical conditions as 
for the acute patient group, including RNA extraction, use of patient matched primers, 
and PCR input volumes. Levels of plasma viremia in the chronic control group were 
<50 copies/ml (mean: 10 copies/ml, range 0-28) and treatment had lasted for a 
median time of 50 weeks (36-183 weeks). In this group of patients, 86% of 
specimens were positive for UsRNA, which is significantly higher than the percentage 
of patients in the acute group showing any UsRNA positive PCR on cART (42%, 
Fisher’s exact test, p=0.008). Furthermore, the average level of UsRNA in the chronic 
control group (mean=272 copies/106 cells, range 0-1486) was 105-fold higher than in 
the acute group (Mann-Whitney, p<0.0001, figure 5A). 
Levels of vDNA were significantly elevated (Mann-Whitney, p=0.04) in the chronic 
group as compared to the patients treated during acute infection. To adjust for this 
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difference in the total number of infected cells, the average viral transcriptional rate 
i.e., the ratio of viral RNA to vDNA, was calculated 11. Similarly as the absolute levels 
of UsRNA, viral transcriptional rates were elevated with high statistical significance 
(12-fold, Mann-Whitney, p=0.0002) in the chronic group as compared to patients in 
the acute group (figure 5B). 
 
 
 
 
 
Figure 5: Viral nucleic acid expression in acute and chronic patients during cART. 
Mean levels of vDNA (grey symbols) and UsRNA (blue symbols) (A) or viral transcription 
rates (B) of patients that had initiated cART during acute infection (acute, n=24, circles) were 
assessed during the on-cART time window (≥24 weeks) and compared to single 
measurements in patients that had initiated cART during chronic infection (chronic, n=15, 
triangles, median treatment time 50 weeks, range 36-183, see Table S1 for details). Data-
points within the grey horizontal areas show PCR-negative samples below the detection limit 
of the assays applied. P-values within panels show significance levels (Mann-Whitney test) 
between the acute and the chronic group. Bars show medians and quartiles. 
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Discussion 
The main aims and rationales for antiretroviral therapy in acute HIV-1 infection are 
confinement of genetic diversity of viral quasispecies to prevent escape from 
adaptive immunity, restriction of CD4+ T-cell loss, preservation of immune functions, 
and inhibition of initial viral spread throughout the possible sites of replication. 
Despite considerable efforts from various research groups, to date evidence from 
clinical studies in humans to empirically substantiate these concepts remains limited. 
Here we performed a longitudinal in-depth analysis using patient matched highly 
sensitive qPCR assays to detect different HIV-1 gene trancripts to assess effects of 
early treatment on cellular reservoirs of HIV-1 in peripheral blood. 
HIV-1 transcription was monitored longitudinally before, during, and after cessation of 
treatment of acute HIV-1 infection in well characterized patients 60,62. This analytical 
approach was applied because numerous studies revealed persistence of cellular 
HIV-1 RNA for years in patients on cART despite suppression of plasma viremia 
14,15,17,57,61,63-65. By choosing a patient matched approach for qPCR with single copy 
sensitivity, it was anticipated that not only levels of UsRNA, but also the less 
abundant multiply spliced RNAs could be quantified and used to assess the viral 
transcription pattern of the PBMC reservoir of HIV-1 during cART 11,12,57. 
The major finding of this study was that early cART initiated during acute HIV-1 
infection significantly depleted the number of transciptionally active proviruses by an 
order of magnitude when compared to levels detected in patients treated during 
chronic infection. 
Specifically, productively infected PBMC, hallmarked by expression of cell attached 
virions (vRex) were depleted within a median time of 4.5 weeks after cART initiation. 
The remaining HIV-1+ PBMC, expressing solely intracellular viral RNA, can therefore 
be viewed as latently infected 11,12,14. These cells faced depletion within a median 
time of 24 weeks. This resulted in >100-fold reduction of viral transcription levels and 
at least 10-fold lower average viral transcriptional rates as compared to patients who 
had started cART during chronic infection. It is unlikely that the strong reduction of 
viral transcription in PBMC in primary HIV infected patients was due to the potency of 
treatment rather than to timing of antiretroviral therapy because the control group of 
chronically infected patients received similar treatment. 
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Decay of HIV-1+ cells in response to treatment occurred in a significantly staggered 
mode according to their pattern of viral RNA expression and life-span as previously 
described 12. Productively infected cells expressing vRex vanished almost instantly 
after initiation of treatment, then cells expressing MsRNA followed with a delay of 
about 4 weeks, ultimately a further 5 weeks later, cells expressing solely UsRNA 
pursued. Thus, even HIV-1 RNA expressing cells with the longest life spans 12 
approached depletion.  
These findings imply that early cART led to the clearance of long-lived cells harboring 
transcriptionally active latent proviruses. In an early study, Markowitz and colleagues 
showed persistence of viral transcription in PBMC when antiretroviral therapy was 
initiated within 90 days after onset of primary symptoms 17. This discrepancy can 
most likely be explained by a 5-6 week earlier initiation of therapy in the present 
study. Of note, our findings are in agreement with the observations of Strain and 
colleagues 46. In their study, using viral outgrowth assays of resting CD4+ T-
lymphocytes, a cohort of patients on early cART showed lower levels of latently 
infected cells than a control group with deferred cART initiation. In addition, two small 
studies in humans and in the SIV model also suggest that HIV-1 suppression as 
measured by unspliced HIV-1, respectively SIV RNA can be reduced by treatment 
during primary HIV infection in the gut associated lymphoid tissue 66,67. 
After cessation of cART, virological parameters reappeared inverted to their decay. 
UsRNA rose to significant levels after 8 weeks, followed two weeks later by MsRNA 
and finally vRex reappeared with a significant delay. The observations that viral 
rebound in plasma preceded that of cellular viral RNAs and plasma viremia was the 
last parameter to decay during cART, implies that PBMC can be viewed as 
independent compartment to some degree separate from the source of virus 
appearing in plasma. These dynamics potentially suggest that repopulation of the 
PBMC compartment of rebounding transcriptionally active PBMC was most likely due 
to “de novo” infection of PBMC by plasma virions rather than by reactivation of 
latently infected PBMC. The rebounding virus most likely originates from distinct 
compartments such as the secondary lymphoid organs (e.g., gut associated 
lymphoid tissue (GALT), lymph nodes, spleen), the cerebral nervous system, the 
kidneys, or the genital tract. Very recent data by Yukl et al. 19 suggests that most 
likely more than 83% of all HIV-1 infected cells under therapy are to be found in the 
GALT and that the RNA/DNA ratio on treatment tends to be higher in this 
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compartment than in the peripheral blood. Furthermore, GALT is continuously 
exposed to bacterial antigenic stimuli from gut commensals. In aggregate, the high 
HIV burden together with continuous antigenic stimulation makes this large reservoir 
a prominent candidate as a source for the rebounding virus. Of note, the RNA/DNA 
ratios of GALT and PBMC in the study by Yukl was measured with exactly the same 
methods as in our study. 
The fact that post-cessation control of viral RNA expression was achieved in several 
patients during the post treatment observation period supports this hypothesis: 
Plasma viremia was undetectable in patient #72, control of UsRNA expression was 
experienced in patient #25, control of MsRNA expression was achieved by patients 
#25, #56, and #92, and control of vRex was experienced by patients #72 and #99. 
The observation that MsRNA-nef levels, a parameter reported to be associated with 
viral latency 57,68 were significantly reduced as compared to baseline further indicates 
that the latent reservoir was reduced by initiation of cART during acute infection. 
Conversely, it cannot be fully excluded that the decreased levels of MsRNA-nef after 
therapy cessation may be explained by the “first peak” of viral replication in acute 
HIV-1 infection and its subsequent spontaneous decay independent of cART 69. 
Taken together, our data demonstrate a profound virologic effect of treatment 
initiation during acute HIV-1 infection. The unprecedented finding that residual viral 
transcription was almost completely depleted, suggests that the latent reservoir of 
HIV-1 during cART can be reduced by early intervention and that proof of concept 
studies aiming at HIV-1 eradication or remission of HIV-1 replication should be 
initiated in patients during acute infection.  
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Materials and Methods 
Ethics Statement: 
In accordance with the guidelines of the Ethics Committee of the University Hospital 
of Zurich, written informed consent was obtained from all participants of the studies 
analyzed: the Zurich Primary HIV Study (ZPHI), the Swiss Spanish Intermittent 
Therapy Trial (SSITT), and the Zurich HIV-1 Transcription Study. 
 
Patients and specimens 
Patients with treatment initiated in the acute phase of HIV-1 infection (acute 
group). Patients (n=24; Table S1) included in our study were enrolled in the Zurich 
Primary HIV Study (ZPHI, http://clinicaltrials.gov, NCT00537966) 62 a substudy of the 
Swiss HIV Cohort Study (SHCS). All 24 subjects had a documented acute or recent 
primary HIV-1 infection at presentation. Estimation of time after infection was as 
described by Rieder et al 60. Patients were included in the analysis only if sequences 
were available to match primers in pol, tat, and env. 
Blood samples were collected at the day of the very first cART application (=baseline 
sample), longitudinally during treatment, and after treatment cessation. EDTA-blood 
samples were collected and separated into cells and plasma according to standard 
procedures 22. Cellular material was split into aliquots, each comprising 2 million 
cells, and finally stored at -80°C as dry cell pellets. Sampling of specimens for 
analysis of plasma viremia and cellular nucleic acids was performed as described in 
Methods S1. All patients were extensively tested for genotypic drug resistance: Only 
one patient showed the D67N mutation at baseline in the routine genotyping test and 
in addition, one patient showed 0.02% K103N and one 2.4% M184V harboring 
minority species 62. 
Patients with treatment initiated in the chronic phase of HIV-1 infection 
(chronic group). PBMC samples for a cross-sectional control group of 15 patients 
treated in the chronic phase after seroconversion were obtained from the Swiss 
Spanish Intermittent Therapy Trial (SSITT) 33 at the last time-point before treatment 
cessation. In addition, specimens collected for The Zurich HIV-1 Transcription Study 
(INFZ VTA 02.00 12) were analyzed (n=9). As in the acute group, patients in the 
chronic group participated also in the Swiss HIV Cohort Study (SHCS) and HIV-1 pol-
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sequences were available from the SHCS genotypic drug resistance database 70. 
Patient characteristics of the chronic group are listed in Table S1. 
 
Nucleic acid extraction/preparation 
Total PBMC RNA was extracted with the RNeasy extraction kit on the ‘QIAcube’ 
extraction device (Qiagen Hombrechtikon, Switzerland) using an initial volume of 
0.35 ml for cell lysis, DNAse I digestion on the extraction column and a final elution 
volume of 0.1 ml. 
Selective isolation of PBMC-associated extracellular, virion-encapsidated genomic 
HIV-RNA, vRex, free of intracellular nucleic acid, was performed as described 14,22,71 
using an elution volume of 0.1 ml. Preparation of protease digested total cell-lysates 
for DNA quantification was performed according to Christopherson et al. 72 with minor 
modifications 11. 
 
Design of HIV-1 patient matched qPCR 
To ensure accurate quantification a patient matched approach reaching single copy 
sensitivity was used for qPCR measurements of RNA and vDNA 11,12,57,58 using 
specifically designed fluorescent hydrolysis probes 58. The location of qPCR primers 
and probes is shown in figure 1; sequences are outlined in detail in Table S2 and 
Methods S1. Individual sequence information to adjust qPCR assays for UsRNA, 
vRex, and vDNA, was obtained from the SHCS genotypic drug resistance database 
(HIV-1 pol-sequences) 70. 
To obtain sequence information to match qPCR primers and probes for MsRNAs of 
predominant quasispecies, two regions were amplified from each patients total DNA 
by a nested PCR scanning approach as described 11 (positions 5833-6152 and 7992-
8567 in the HXB2 genome, GenBank accession number K03455). 
As previously described 11,12,57 two different assays for MsRNA were performed: 
MsRNA-total and MsRNA-tatrev from which the MsRNA-nef was calculated using the 
difference in copy numbers between the two measurements. To avoid redundancy, 
MsRNA-total was not reported. Thus, only MsRNA-tatrev and MsRNA-nef are shown 
in the current data-set and used for statistical calculations. In 11% of measurements, 
it occurred that copy numbers of MsRNA-total were nominally lower or equal to 
MsRNA-tatrev. Calculation of MsRNA-nef was considered as not applicable in these 
cases. 
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Quantitative real-time PCR measurements 
Assays for RT-qPCR were performed as described 57,73 using an ABI 7500 real-time 
thermocycler (Applied Biosystems, Rotkreuz, Switzerland) with 0.005µM ROX as 
passive reference, 0.2 µM fluorescent probe and 5 µl RNA as template in a final 
volume of 35 µl aqueous phase plus 15 µl paraffin. Quantification of vDNA was 
performed as described by Althaus et al. 58 in an IQ5 real-time thermocycler (Biorad, 
Basel, Switzerland) in a volume of 60 μl with 10 μl DNA template using HotStarTaq 
master mix (QIAGEN, Hilden, Germany) supplemented with PCR primers (1 μM 
each), probe (0.3 μM), and additional MgCl2 (1.5 μM) by incubation for 15 min at 
95°C and 60 cycles of 10 s at 95°C, 5 s at 55°C and 40 s at 60°C. 
 
Calculation of HIV-1 nucleic acid copy numbers from qPCR data 
Patient-nucleic acids were directly used to generate HIV-1 standard-curves. To 
obtain standard curves with maximal dynamic range, baseline specimens were used 
as standards for vDNA-measurements. Post-cessation time points with high plasma 
viremia and high vDNA were chosen. Standards were prepared as serial 3-fold 
dilutions in quadruplicates. Specimens other than the ones chosen as standards 
were measured in duplicate. 
Linear regression used in standard real-time PCR analysis was applied for 
calculation of HIV-1 copy numbers: 
Equation 1) Ct = I + S x log10 (copy numbers), 
where I is the Y-axis intercept of the regression line, depicting the point where Ct 
equals one copy (=100) and S is its slope. I and S were determined as described in 
Methods S1. In cases where only one duplicate HIV-1 PCR was positive and/or 
calculation resulted in less than 1 nominal copy number per reaction, HIV-1 nucleic 
acid copy numbers were censored to 1 copy per PCR 11,12. 
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Normalization to cellular input 
To control for input and/or differences in qPCR efficiencies in RNA PCR the 
expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) against a 
standard dilution series of in vitro transcribed GAPDH RNA was measured in 
duplicates as described previously 73 and in Methods S1. Linear regression, as 
applied by the ABI7500 software, was used to evaluate GAPDH measurements. 
Mean GAPDH-RNA copies per 106 cell equivalents were empirically determined in 
PBMC specimens with known cell numbers (2 x106 cells sample, n=310) resulting in 
a conversion factor of 2.85 x107 copies GAPDH-RNA/106 PBMC. 
Cellular input for DNA was quantified by beta-actin PCR using primers and probe 
described in Methods S1. As quantification standard for cellular input, 15 million 
PBMC were lysed in 1 ml cell lysis buffer, serial two-fold dilutions were measured 
and cellular input per PCR was calculated by linear regression using the software 
provided with the IQ5-system. Both for vDNA and viral RNA, the mean of duplicate 
PCR measurements was normalized to cellular input and finally expressed as HIV-1 
nucleic acid copies per 106 PBMC. 
 
Statistical analysis 
GraphPad Prism 5.0 software (GraphPad Software, San Diego, CA) was used for 
statistical analyses. P<0.05 was considered as the level of significance. Mann-
Whitney testing was applied unless otherwise indicated for group comparisons. 
Fisher’s exact test was used in analysis of contingency tables. No adjustment for 
multiple testing was applied. 
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Conclusions and Outlook 
Combination antiretroviral therapy has tremendously reduced morbidity and mortality 
of HIV-1 infected patients4. Nevertheless, HIV-1 infection can not be cured. The main 
obstacle is the presence of latently infected cells which contain proviral DNA that is 
transcriptionally not active, however, may be activated and produce virions upon 
certain stimuli37,40,45. The three projects described in this thesis approach different 
aspects of HIV-1 latency.  
In the first project, prerequisites for the optimal design of qPCR for phylogenetically 
diverse organisms, such as HIV-1108, were defined. Highly sensitive qPCR is 
particularly needed to quantify RNA transcripts in latently HIV-1 infected cells from 
patients, successfully treated with cART. Primers can be relatively forgiving in 
respect to target variation109, but also their optimal design and target 
complementarity should be considered for highly sensitive qPCR assays. However, 
we were focusing on the fluorescent hydrolysis probes (FH-probes), as they are very 
sensitive to mismatches in their target recognition site110, which could lead to an 
underestimation of RNA copy numbers in the case of highly variable HIV-1. On the 
other hand, they are the most sensitive reagents to quantify specifically genome copy 
numbers by qPCR111. Thus, more than 50 FH-probes have been investigated in 
terms of their performance in qPCR assays. Our data allowed to determine positive 
predictors for optimal functionality, for instance, a purine at the second position of the 
5’ end, a high melting temperature of the 5’ end, and the presence of G/C rich 
secondary structures predict a efficient FH-probe performance in qPCR assays112. 
Additionally, application of an algorithm to scan sequence databases for FH-probes 
with optimal phylogenetic conservation enabled the identification of functional FH-
probes in various regions of the HIV-1 genome approaching coverage of the global 
HIV-1 pandemic. The established phylogenetic and biochemical principles for FH-
probe and qPCR design may also be extended to other phylogenetically diverse 
biological systems. 
A first application of those highly sensitive qPCR assays is shown in the third project. 
HIV-1 transcription was monitored in PBMC of acutely HIV-1 infected patients to 
determine the effects of early treatment. Especially for measuring the different HIV-1 
transcripts in patients under successful treatment single copy sensitive PCRs are 
needed. Interestingly, cART initiated during acute HIV-1 infection significantly 
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depleted the number of transcriptionally active proviruses by an order of magnitude 
when compared to levels detected in patients starting cART during chronic HIV-1 
infection113. 
In summary, highly sensitive qPCRs are essential when very low levels of the 
different HIV-1 transcripts are expected. Also further studies, analyzing possible 
latency mechanisms and treatment options to cure HIV-1, will depend on highly 
sensitive PCR assays. 
 
In the second project, a novel method was established to enrich low abundant, small 
noncoding RNAs (sncRNAs). HIV-1 sncRNAs are generated in very low frequencies 
in HIV-1 infected cells, if at all (0-<0.5%)80,98,107. So far, only a few HIV-1 derived 
sncRNAs have been described82,84,85,101,102. We hypothesize that HIV-1 latency might 
be induced by RNA interference, a post-transcriptional silencing pathway ubiquitously 
present in eukaryotic cells of many organisms and mediated by sncRNAs114. Thus, 
the first step to prove this hypothesis was the development of an enrichment method 
to detect HIV-1 derived sncRNAs. More than 100-fold enrichment could be achieved 
using our hybridization capture based enrichment protocol, which includes two 
rounds of selection where HIV-1 derived sncRNAs bind specifically to long HIV-1 
ssDNA hybridization probes covering the whole virus genome. This method was 
applied to several HIV-1 infected primary macrophages and CD4+ T-lymphocytes 
showing its reproducibility, sensitivity, and specificity. SncRNA libraries obtained with 
our method contained more than 70% of HIV-1 derived sncRNAs. While high-
throughput sequencing techniques certainly have the capacity to overcome the 
limitations in identifying low abundant sncRNAs, it must still be considered that more 
than 99% of sequenced sncRNAs retrieved by random sequencing will not be of 
interest and very low abundant sncRNAs might still be missed. Our approach allows 
sequence specific selection with a high sensitivity, i.e., all captured sncRNAs are of 
potential interest even if they are not derived from HIV-1. Certainly, also a combined 
approach, hybridization capture followed by high-throughput sequencing instead of 
molecular cloning and Sanger sequencing, should be conceivable and would 
combine advantages of both methods.   
 
With this highly optimized method, 216 unique, HIV-1 derived clones were identified 
from a total of 9 sncRNA libraries. Those were distributed throughout the viral 
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genome; however, they tend to cluster in certain regions of the viral genome where 
these >200 sncRNAs formed 67 contigs. An obvious question that arises is whether 
the HIV-1 sncRNAs detected here are not just mere degradation products. There are 
several points arguing against it. Firstly, the HIV-1 sncRNAs are not randomly 
distributed as it would be expected in case of degraded products, but are rather 
localized in certain hot-spots at distinct sites. One could still argue that certain 
degraded RNA fragments are protected from further degradation due to their 
secondary structure. However, no evidence for preferential clustering in highly 
structured regions of the HIV-1 genome10 were observed (except HIV-1 sncRNAs  
within the TAR region). Secondly, the enzymes used for C-tailing and adaptor ligation 
require specific ends, namely a phosphate at the 5’ end and a hydroxyl at the 3’ end 
which are not produced by the common RNA degradation process via hydrolysis115. 
Thirdly, HIV-1 sncRNAs were identified that correspond to the regions where HIV-1 
sncRNAs (hiv-1-miR-TAR-3p, hiv-1-miR-H1, and hiv1-miR-N367) have been 
described previously84,85,102. 
At last, further characterization of these HIV-1 derived sncRNAs was started. The 
presence of 4 sncRNAs contigs from different regions of the viral genome was 
confirmed in cells infected with primary virus isolates derived from 5 different HIV-1 
patients, which excluded the possibility that these sncRNAs are specific for the virus 
isolate HIV-1JRFL used for all former experiments. Additionally, functional assays were 
performed by transfecting primary macrophages with two HIV-1 sncRNAs contigs. 
This identified one contig, consisting of sense and antisense sncRNAs, which 
efficiently inhibited HIV-1 replication. 
The next steps will be to further characterize the functions of the identified HIV-1 
sncRNAs as well as their biogenesis pathways. Most of the clones are in sense 
direction and therefore not able to target the plus-sense, single-stranded RNA 
genome of HIV-1 at the accordant position. Nevertheless, they might target other 
positions in the HIV-1 genome or human cellular RNA transcripts. Interestingly, 
approximately 10% of the HIV-1 sncRNAs are in antisense direction, thus, they could 
hybridize to the HIV-1 RNA genome and inhibit virus replication via the RNA 
interference pathway. Besides investigating their potential as HIV-1 inhibitors, it 
needs to be explored how antisense sncRNAs are generated. It is generally assumed 
that HIV-1 antisense transcripts are not generated14, however, there are few reports 
showing that antisense transcripts are produced in low levels116-118. Those transcripts 
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might either be initiated by the HIV-1 promoter located in the 3’ LTR119 or by a 
downstream cellular promoter120. Nevertheless, it is still unknown whether they are 
just random by-products, or if they have specific functions121. One possible function 
could be that they are processed to regulatory small RNAs, and lead to a 
downregulation of HIV-1 transcription, which could ultimately lead to HIV-1 latency. 
Another hypothesis is that they might upregulate HIV-1 replication, especially the 
sncRNAs targeting the promoter region122,123, and therefore rather present a way for 
the virus to control its reactivation after latency . In case those sncRNAs would have 
opposite effects, this would open a variety of options for developing novel treatment 
strategies.  
To experimentally further address the potential functions of the HIV-1 sncRNAs, HIV-
1 sncRNA transfection/HIV-1 infection experiment should be performed to asses their 
impact on HIV-1 replication. Furthermore, their interaction with, for instance, Ago or 
PIWI could be investigated by immunoprecipitation. For HIV-1 sncRNAs having an 
impact on HIV-1 replication and interacting with RNAi pathway proteins, an in silico 
target screening could be performed on both the viral and the cellular mRNA 
transcripts. 
In conclusion, our method presents a validated and very efficient approach to enrich 
and identify novel, low abundant HIV-1 sncRNAs. HIV-1 derived sncRNAs are a very 
exciting field, which could have an enormous impact on novel therapy designs. There 
are currently numerous siRNAs tested for treatment of, for instant, cancer124,125 and 
infectious diseases126 (clinicaltrials.gov). 
In summary, our selection method has an enormous capacity to enrich low abundant 
sncRNAs in a sequence specific manner, which highly recommends its usage also 
for the detection of sncRNAs of other origins. The method can be applied for any 
type of investigations where sncRNAs from known origins or hybridizing to a known 
target sequence are sought for. 
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Abbreviations 
AATF apoptosis antagonizing transcription factor 
Ago Argonaut 
AIDS  acquired immunodeficiency syndrome 
APOBEG3G apoliprotein B mRNA editing enzyme, catalytic polypeptide-like 3G 
bp  base pair 
CA  capsid 
cART  combination antiretroviral therapy 
cDNA  complementary DNA 
Ct  treshhold cycle 
Delta-Tm Tm difference of FH-probe and the primer binding the same strand 
DIS dimerization initiation site 
DLNA DNA locked nucleic acid 
DNA  deoxyribonucleic acid 
dsRNA  double-stranded RNA 
EBV Epstein-Barr virus 
Env  envelope 
FH-probe fluorescent hydrolysis probe 
Gag  group specific antigen 
GALT gut associated lymphoid tissue 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
HAT Histone acetyltransferase 
HDAC1 Histone deacetylase 1 
HIV  Human immunodeficiency virus 
IN integrase 
KSHV Kaposi’s sarcoma-associated herpesvirus 
LTR  Long Terminal Repeat 
MA  matrix 
miRNA  microRNA 
mRNA  messenger RNA 
MsRNA multiply spliced RNA 
NC  nucleocapsid 
ncRNA  noncoding RNA 
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Nef  negative replication factor 
NF-κB  nuclear factor kappa b 
nt  nucleotide 
PBMC  peripheral blood mononuclear cell 
PBS primer binding site 
PCAF p300/CBP-associated factor 
PCR  polymerase chain reaction 
PHA  phytohaemagglutinin 
piRNA  Piwi-interacting RNA 
Pol  polymerase 
PR  protease 
Pre-miRNA precursor microRNA 
P-TEFb  Positive transcription elongation factor b 
qPCR quantitative polymerase chain reaction 
R repeat region in the LTR 
Rev  Regulator of virion expression 
RISC  RNA-induced silencing complex 
RNA  ribonucleic acid 
RNAi  RNA interference 
RRE  Rev responsive element 
rRNA  ribosomal RNA 
RT  reverse transcriptase 
RT-PCR  reverse transcription-PCR 
sA7 splice acceptor 7 
SHCS Swiss HIV Cohort Study 
siRNA  small interfering RNA 
sncRNA  small noncoding RNA 
SNR signal to noise ratio 
ssRNA single stranded RNA 
SU  surface glycoprotein 
TAR  trans-activating response region 
Tat  transactivator of transcription 
Tm  melting temperature 
TM  transmembrane glycoprotein 
ABBREVIATIONS 
 122
TRBP  TAR RNA binding protein 
tRNA  transfer RNA 
TSA trichostation A 
UsRNA unspliced RNA 
vDNA viral DNA 
vmiRNA viral micro RNA 
vsiRNA viral small interfering RNA 
VPA valproic acid 
Vpr  Viral protein R 
Vpu  Viral protein 
vRex PBMC-associated extracellular virion RNA 
ZPHI Zurich Primary HIV Study 
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